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With the increase in life expectancy, the prevalence of cognitive disorders is expected to 
further rise the coming years.(1) The number of people suffering from dementia worldwide 
is estimated to almost double every 20 years, with prevalence numbers of 65.7 million in 
2030 and 115.4 million in 2050.(1) Accumulating evidence of the last years highlights the 
role of cardiovascular risk factors in the pathogenesis of cognitive disorders.(2-4) Epide-
miological, pathological and neuroimaging studies show that cardiovascular risk factors 
in middle age associate with an increased risk of brain aging and cognitive impairment 
in later life.(5, 6) In older people, however, the contribution of cardiovascular risk factors 
in the development of cognitive impairment is still a matter of debate.(7) Furthermore, 
although a variety of mechanisms have been proposed to explain the association of car-
diovascular risk factors with cognitive disorders, the underlying pathways have not been 
fully understood.
An example of a cardiovascular risk factor in middle age that is associated with cognitive 
impairment in later life, is high blood pressure.(8) Numerous studies demonstrate that 
midlife high blood pressure is a risk factor for cardiovascular events, brain atrophy, and 
cognitive decline.(9-12) In addition, some randomized controlled trials show favorable 
effects of midlife antihypertensive treatment on risk of cognitive impairment.(13, 14) 
However, recent evidence shows that this association attenuates with increasing age and 
it has even been reported that in older age, low instead of high blood pressure relates 
with increased risk of cognitive disorders and cardiovascular events.(6, 15-17) In particular 
people who are biologically older seem to suffer from low blood pressure values.(18-20) 
Besides blood pressure, cardiac disease is associated with increased risk of cognitive dis-
orders and dementia. Patients with coronary artery disease, atrial fibrillation, and chronic 
heart failure have worse cognitive function and a higher risk of progression to dementia.
(3, 21-23) A possible explanation behind this association is reduced cardiac output, leading 
to cerebral hypoperfusion and subsequently to impairment of delivery of oxygen and nutri-
ents to the brain.(3) Concordantly, it has been shown that in patients with severe systolic 
heart failure, cognitive function significantly improved after a cardiac transplantation, or 
after implantation of a left ventricular assist device.(24, 25) However, whether people with 




The aims of this thesis are 1) to further investigate whether blood pressure in older people 
is a risk factor for cardiovascular events and cognitive impairment; 2) to study whether 
early markers of cardiac disease are related with cognitive impairment; and 3) to evaluate 
the feasibility of home blood pressure monitoring using smartphone-assisted technology, 
which might eventually assist to prevent cognitive impairment.
Outline of this thesis
This thesis is divided in three parts. The first part consists three studies evaluating the associa-
tion of blood pressure and blood pressure variability with cardiovascular events and cognitive 
function in older age, respectively. Chapter 2 evaluates whether the association between 
(diastolic) blood pressure and cardiovascular events differs in people with and without a 
history of cardiovascular disease. Besides average blood pressure, visit-to-visit blood pressure 
variability has been associated with cardiovascular events and cognitive impairment. In chap-
ter 3, we therefore study the association of visit-to-visit blood pressure variability with cogni-
tive function. Furthermore, we investigate potential explanations behind this association in 
a magnetic resonance substudy. Chapter 4 further elaborates on this topic by studying how 
blood pressure lowering medication is related to both visit-to-visit blood pressure variability 
and cognitive function; and whether blood pressure lowering medication could explain the 
relation between visit-to-visit blood pressure variability and cognitive impairment.
The second part of this thesis consists of two studies addressing the association between 
early markers of cardiac disease and cognitive function. In chapter 5, we evaluate the 
relation of N-terminal pro-brain natriuretic peptide (NT-proBNP), a neurohormone that 
is commonly used in the diagnosis of clinical heart failure, with cognitive function and 
decline. Furthermore, chapter 6 investigates whether cardiac troponin T (cTnT), routinely 
used in the diagnosis of acute myocardial infarction, associates with cognitive function. 
Part three includes the translation of results of previous studies into an innovative method, 
focused on the prevention of cognitive impairment. The online research platform iVital-
ity, that comprises a website, a smartphone-based application and health sensors, was 
designed to perform large-scale studies in an aging population at risk for cognitive im-
pairment. Chapter 7 describes the first results of a proof-of-principle study, in which we 
evaluated the feasibility of home blood pressure monitoring using iVitality.
In chapter 8 the main conclusions of this thesis are summarized and discussed, and future 





 1. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: 
a systematic review and metaanalysis. Alzheimers Dement 2013;9(1):63-75.
 2. Abete P, Della-Morte D, Gargiulo G, Basile C, Langellotto A, Galizia G, Testa G, Canonico V, 
Bonaduce D, Cacciatore F. Cognitive impairment and cardiovascular diseases in the elderly. A 
heart-brain continuum hypothesis. Ageing Res Rev 2014;18:41-52.
 3. Eggermont LH, de BK, Muller M, Jaschke AC, Kamp O, Scherder EJ. Cardiac disease and cogni-
tive impairment: a systematic review. Heart 2012;98(18):1334-1340.
 4. Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, Launer LJ, Laurent S, 
Lopez OL, Nyenhuis D, Petersen RC, Schneider JA, Tzourio C, Arnett DK, Bennett DA, Chui HC, 
Higashida RT, Lindquist R, Nilsson PM, Roman GC, Sellke FW, Seshadri S. Vascular contribu-
tions to cognitive impairment and dementia: a statement for healthcare professionals from the 
american heart association/american stroke association. Stroke 2011;42(9):2672-2713.
 5. Debette S, Seshadri S, Beiser A, Au R, Himali JJ, Palumbo C, Wolf PA, Decarli C. Midlife vas-
cular risk factor exposure accelerates structural brain aging and cognitive decline. Neurology 
2011;77(5):461-468.
 6. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood 
pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 
prospective studies. Lancet 2002;360(9349):1903-1913.
 7. Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive 
function and dementia. Lancet Neurol 2005;4(8):487-499.
 8. Kennelly SP, Lawlor BA, Kenny RA. Blood pressure and the risk for dementia: a double edged 
sword. Ageing Res Rev 2009;8(2):61-70.
 9. den Heijer T, Launer LJ, Prins ND, van Dijk EJ, Vermeer SE, Hofman A, Koudstaal PJ, Breteler 
MM. Association between blood pressure, white matter lesions, and atrophy of the medial 
temporal lobe. Neurology 2005;64(2):263-267.
 10. Korf ES, White LR, Scheltens P, Launer LJ. Midlife blood pressure and the risk of hippocampal 
atrophy: the Honolulu Asia Aging Study. Hypertension 2004;44(1):29-34.
 11. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Soininen H, 
Tuomilehto J, Nissinen A. Midlife vascular risk factors and Alzheimer’s disease in later life: 
longitudinal, population based study. BMJ 2001;322(7300):1447-1451.
 12. Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR, Havlik RJ. Midlife blood pres-
sure and dementia: the Honolulu-Asia aging study. Neurobiol Aging 2000;21(1):49-55.
 13. Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, Bossini A, Fagard R, 
Gil-Extremera B, Laks T, Kobalava Z, Sarti C, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, 
Birkenhager WH. The prevention of dementia with antihypertensive treatment: new evidence 
from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002;162(18):2046-
2052.
 14. in’t Veld BA, Ruitenberg A, Hofman A, Stricker BH, Breteler MM. Antihypertensive drugs and 
incidence of dementia: the Rotterdam Study. Neurobiol Aging 2001;22(3):407-412.
 15. Boutitie F, Gueyffier F, Pocock S, Fagard R, Boissel JP. J-shaped relationship between blood pres-
sure and mortality in hypertensive patients: new insights from a meta-analysis of individual-
patient data. Ann Intern Med 2002;136(6):438-448.
 16. Protogerou AD, Safar ME, Iaria P, Safar H, Le DK, Filipovsky J, Henry O, Ducimetiere P, Blacher J. 
Diastolic blood pressure and mortality in the elderly with cardiovascular disease. Hypertension 
2007;50(1):172-180.
 17. Voko Z, Bots ML, Hofman A, Koudstaal PJ, Witteman JC, Breteler MM. J-shaped relation 
between blood pressure and stroke in treated hypertensives. Hypertension 1999;34(6):1181-
1185.
 18. Muller M, Maier AB, Smulders YM. [High blood pressure and mortality in the elderly: what 
does gait speed tell?]. Ned Tijdschr Geneeskd 2013;157(7):A5801.
Chapter 1
12
 19. Post HG, Smulders YM, Maier AB, Deeg DJ, Muller M. Relation between blood pressure and 
mortality risk in an older population: role of chronological and biological age. J Intern Med 
2014.
 20. Odden MC, Peralta CA, Haan MN, Covinsky KE. Rethinking the association of high blood pres-
sure with mortality in elderly adults: the impact of frailty. Arch Intern Med 2012;172(15):1162-
1168.
 21. Qiu C, Winblad B, Marengoni A, Klarin I, Fastbom J, Fratiglioni L. Heart failure and risk 
of dementia and Alzheimer disease: a population-based cohort study. Arch Intern Med 
2006;166(9):1003-1008.
 22. Vogels RL, Scheltens P, Schroeder-Tanka JM, Weinstein HC. Cognitive impairment in heart 
failure: a systematic review of the literature. Eur J Heart Fail 2007;9(5):440-449.
 23. Zuccala G, Marzetti E, Cesari M, Lo Monaco MR, Antonica L, Cocchi A, Carbonin P, Bernabei R. 
Correlates of cognitive impairment among patients with heart failure: results of a multicenter 
survey. Am J Med 2005;118(5):496-502.
 24. Zimpfer D, Wieselthaler G, Czerny M, Fakin R, Haider D, Zrunek P, Roethy W, Schima H, Wolner 
E, Grimm M. Neurocognitive function in patients with ventricular assist devices: a comparison 
of pulsatile and continuous blood flow devices. ASAIO J 2006;52(1):24-27.
 25. Gruhn N, Larsen FS, Boesgaard S, Knudsen GM, Mortensen SA, Thomsen G, Aldershvile J. 





Blood pressure, cognitive function and mortality

Chapter 2
Association of diastolic blood pressure with 
cardiovascular events in older people varies upon 
cardiovascular history
Liselotte W Wijsman, Majon Muller, Anton JM de Craen, J Wouter Jukema, 





Background In older age, a low diastolic blood pressure (DBP) has been associated with 
increased risk of cardiovascular events, especially in frail older people. A potential mecha-
nism might be that low DBP leads to inadequate perfusion of vital organs. Here, we tested 
the hypothesis that low DBP is associated with a high risk of cardiovascular events in 
people with a previous history of cardiovascular disease, as a proxy of vascular impairment. 
Methods We included 5,804 participants (mean age 75 years) from the PROspective Study 
of Pravastatin in the Elderly at Risk (PROSPER) who as part of the trial were intensively 
monitored for an average period of 3.2 years. Baseline DBP was categorized in low (<70 
mmHg), normal (70-90 mmHg) or high (>90 mmHg). Cox proportional hazards analyses 
were used to estimate hazard ratio (HR) with 95% confidence intervals (CI) for the associa-
tion of DBP with cardiovascular events. Analyses were stratified for cardiovascular history.
Results We show that participants with low DBP had an 1.24-fold (95% CI 1.04; 1.49) 
increased risk of cardiovascular events compared to those with normal DBP. After further 
adjusting for cardiovascular factors, this association attenuated to 1.05 (95% CI 0.86; 
1.28). A previous history of cardiovascular disease significantly modified the relation 
between DBP and risk of cardiovascular events (p for interaction=0.042). In participants 
without a history of cardiovascular disease, DBP was marginally significant associated with 
an increased event risk (HR (95% CI) per 10 mmHg increase in DBP 1.08 (0.99; 1.18), 
p-value=0.07), whereas in participants with a history of cardiovascular disease higher DBP 
was associated with a decreased risk of cardiovascular events (HR (95% CI) per 10 mmHg 
increase in DBP 0.92 (0.85; 0.99, p-value=0.018). These risk estimates were independent 
of potential confounders, including classical cardiovascular risk factors.
Conclusion The association of DBP with cardiovascular events in older people varies upon 
their previous history, showing that in participants with pre-existing cardiovascular disease 
a higher DBP associates with a decreased risk of future cardiovascular events.




The association between blood pressure and cardiovascular events has been studied in 
numerous observational studies.(1-11) Despite a large body of evidence showing that 
high systolic and diastolic blood pressure are risk factors for cardiovascular disease in 
middle-aged people, the association is less evident in older age.(10, 12) Several studies in 
older people showed an attenuating relation between blood pressure and occurrence of 
myocardial infarction, stroke, and vascular and all-cause mortality.(2, 3, 5, 9, 12)
Recent data found that the risk associated with lower levels of blood pressure was even 
reversed in frail older people.(6, 8, 10, 13, 14) A population-based study including 599 of 
the oldest old (85 years or older) showed that blood pressure values below 140/90 mmHg 
were associated with excess mortality.(10) Furthermore, observational studies found that 
low blood pressure was associated with higher risk of cardiovascular events, but only in 
people with impaired physical and cognitive function, used as a marker of vascular impair-
ment.(6, 8, 14) This finding was in particular the case for low diastolic blood pressure.
(6, 8) This poses the hypothesis that instead of chronological age, it might be vascular 
impairment that explains that the association between low diastolic blood pressure and 
cardiovascular risk reverses. 
We therefore hypothesized that low diastolic blood pressure, independent of systolic 
blood pressure, is associated with an increased risk of cardiovascular events in people 
with a previous history of cardiovascular disease, as a proxy of vascular impairment. The 
aims of this study were 1) to investigate the association of diastolic blood pressure with 
cardiovascular events, and 2) to study whether this association differed in people with 
and without a previous cardiovascular history. We used data of the PROspective Study of 
Pravastatin in the Elderly at Risk (PROSPER), which included older participants (70-82 years) 
with a cardiovascular history and participants without a cardiovascular history, but with 




Study design and participants
We used data from the PROspective Study of Pravastatin in the Elderly at Risk (PROS-
PER), a randomized, placebo-controlled trial designed to investigate whether treatment 
with pravastatin would diminish the occurrence of vascular events in participants with 
pre-existing cardiovascular diseases or risk factors thereof. PROSPER included 5,804 par-
ticipants, aged 70-82 years, from three collaborating centers in Ireland, Scotland and the 
Netherlands.15 Approximately 50% of all participants had a history of cardiovascular dis-
eases, including stable angina, intermittent claudication, stroke, transient ischemic attack, 
myocardial infarction, and vascular surgery. The rest of the participants had one or more 
major cardiovascular risk factors, defined as hypertension, cigarette smoking, or diabetes 
mellitus. Primary outcome of the trial is the composite outcome of coronary heart disease 
death, non-fatal myocardial infarction, and fatal or non-fatal stroke. Details of the design 
and outcome of the PROSPER have been published elsewhere.(15) 
Blood pressure measurements
Blood pressure was measured at two consecutive moments at baseline, in sitting position, 
with a fully automatic electronic sphygmomanometer (Omron M4H) by trained research 
nurses. Baseline blood pressure was defined as the mean value of the two blood pressure 
measurements. Diastolic blood pressure was categorized based on three clinically relevant 
cutoff level: low (<70 mmHg), normal (70-90 mmHg) and high (>90 mmHg). 
Outcomes 
Information on the occurrence of cardiovascular events was collected during the course 
of PROSPER, which had a mean follow-up period of 3.2 years. Cardiovascular events were 
defined as definite or suspect death from coronary heart disease, non-fatal myocardial 
infarction, fatal or non-fatal stroke / transient ischemic attack, coronary artery bypass 
graft or percutaneous transluminal coronary angioplasty or peripheral arterial surgery or 
angioplasty.(16) 
Statistical analysis
Baseline characteristics were calculated for all participants and for participants with low, 
normal and high diastolic blood pressure at baseline. Baseline differences in continuous 
variables were tested with linear regression models; Chi-squared tests were used to test 
differences in categorical variables. 
Association of diastolic blood pressure with cardiovascular events
2
21
We used Cox proportional hazards analyses to estimate hazard ratio’s (HR) with 95% 
confidence intervals (CI) for the association of diastolic blood pressure with risk of car-
diovascular events. Participants with normal diastolic blood pressure (70-90 mmHg) were 
taken as reference category. To investigate the association of diastolic blood pressure 
with cardiovascular events in participants with and without a cardiovascular history, we 
stratified our analyses for history of cardiovascular disease. To study whether the trend 
for cardiovascular events among the diastolic blood pressure groups was significant, we 
calculated a probability (p) value by using diastolic blood pressure as a continuous variable. 
Furthermore, we analysed whether the association between diastolic blood pressure and 
cardiovascular events differed in participants with and without cardiovascular history. For 
this, we calculated the interaction term between diastolic blood pressure (as a continuous 
variable) and history of cardiovascular disease; and included this interaction term together 
with diastolic blood pressure (as a continuous variable) and history of cardiovascular disease 
in the Cox proportional hazards analyses. All Cox regression analyses were adjusted for the 
following sociodemographic variables: sex, age, country and treatment during follow-up 
of the study (pravastatin or placebo). We additionally adjusted the analyses for potential 
cardiovascular confounders, including systolic blood pressure, histories of hypertension, 
diabetes, smoking, body mass index (BMI), estimated glomerular filtration rate (eGFR), 
N-terminal pro-brain natriuretic peptide (NT-proBNP), cardiac troponin T, and high-density 
lipoprotein (HDL), low-density lipoprotein (LDL) and triglyceride levels at baseline.
In addition, we explored the association between systolic blood pressure with cardiovas-
cular events. Again, participants with normal systolic blood pressure (120-140 mmHg) 
were taking as a reference category. All Cox regression analyses were adjusted for sociode-
mographic variables (sex, age, country and treatment during follow-up of the study) and 
additionally for potential cardiovascular confounders, including diastolic blood pressure, 
histories of hypertension, diabetes, smoking, body mass index (BMI), estimated glomerular 
filtration rate (eGFR), N-terminal pro-brain natriuretic peptide (NT-proBNP), cardiac tropo-
nin T, and high-density lipoprotein (HDL), low-density lipoprotein (LDL) and triglyceride 
levels at baseline.
All analyses were performed using SPSS software (version 20.0.0, SPSS Inc., Chicago, IL). 




Table 1 shows the baseline characteristics for all 5,804 study participants and in groups 
of diastolic blood pressure at baseline. Mean age of all participants was 75.3 years; par-
ticipants with higher diastolic blood pressure were younger; 3,000 participants (51.7%) 
were female. Participants with a higher diastolic blood pressure had higher systolic blood 
pressure, higher pulse pressure, and a higher prevalence of hypertension. Participants with 
lower diastolic blood pressure had a higher prevalence of cardiovascular disease, history of 













Systolic blood pressure 133.2 (0.7) 153.0 (0.3) 169.6 (0.5) <0.001
Diastolic blood pressure 65.5 (0.2) 81.7 (0.1) 98.3 (0.2)
Pulse pressure 67.7 (0.7) 71.3 (0.3) 71.3 (0.5) 0.023
Demographics
Age (years) 75.6 (0.1) 75.4 (0.1) 75.1 (0.1) 0.024
Female, n (%) 344 (49.3%) 1958 (52.9%) 698 (49.7%) 0.048
Vascular risk factors
History of hypertension, n (%) 292 (41.8%) 2275 (61.5%) 1025 (73.0%) <0.001
History of diabetes mellitus, n (%) 73 (10.5%) 375 (10.1%) 175 (12.5%) 0.055
History of stroke or TIA, n (%) 69 (9.9%) 428 (11.6%) 152 (10.8%) 0.384
History of MI, n (%) 150 (21.5%) 491 (13.3%) 135 (9.6%) <0.001
History of vascular disease, n (%) 412 (59.0%) 1647 (44.5%) 506 (36.0%) <0.001
Current smoker, n (%) 221 (31.7%) 1001 (27.0%) 336 (23.9%) 0.001
Body mass index (kg/m2) 25.7 (0.2) 26.8 (0.1) 27.6 (0.1) <0.001
LDL cholesterol (mmol/L) 3.8 (0.0) 3.8 (0.0) 3.8 (0.0) 0.581
HDL cholesterol (mmolL) 1.3 (0.0) 1.3 (0.0) 1.3 (0.0) 0.482
Triglycerides (mmol/L) 1.5 (0.0) 1.5 (0.0) 1.6 (0.0) 0.247
Blood pressure lowering medication, n (%)
Diuretics 251 (36.0%) 1517 (41.0%) 590 (42.0%) 0.022
Ace-inhibitors 105 (15.0%) 562 (15.2%) 284 (20.2%) <0.001
Beta-blockers 199 (28.5%) 947 (25.6%) 356 (25.3%) 0.235
Calcium channel blockers 218 (31.2%) 947 (25.6%) 293 (20.9%) <0.001
Biochemistry
eGFR (ml/min/1.73m2) 59.5 (0.6) 59.8 (0.2) 60.8 (0.4) 0.025
NT-proBNP (ng/L) 375.7 (21.5) 279.1 (9.3) 293.7 (15.1) 0.547
Cardiac troponin T (ng/L) 10.1 (1.4) 9.2 (0.6) 13.4 (1.0) 0.021
Data represent mean (standard error), unless stated otherwise. Abbreviations: TIA, transient ischemic attack; MI, myo-
cardial infarction; eGFR, estimated glomerular filtration rate; NT-proBNP, N-terminal pro-brain natriuretic peptide. 1P-
value for continuous variables was calculated by using DBP as continuous variable. 
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myocardial infarction and smoking. No differences existed in prevalence of diabetes mel-
litus and stroke or transient ischemic attack between the diastolic blood pressure groups. 
A total number of 977 participants (16.8%) experienced a cardiovascular event during 
the mean follow-up period of 3.2 years. Across the total population, participants with 
low diastolic blood pressure (<70 mmHg) had a 1.24-fold (1.04; 1.49) increased risk of 
cardiovascular events (HR (95% CI) compared to those with normal diastolic blood pres-
sure). After adjusting for cardiovascular risk factors, the association between diastolic 
blood pressure and cardiovascular events attenuated to 1.11 (0.90; 1.37). When compared 
to normal diastolic blood pressure, high diastolic blood pressure (>90 mmHg) was not 
associated with an increased cardiovascular event risk (0.91 (0.76; 1.107)).
To further study the association between diastolic blood pressure and cardiovascular 
events, we investigated whether the association differed in participants with and without 
a previous history of cardiovascular disease as a marker of vascular impairment. History 
of cardiovascular disease significantly modified the relation between diastolic blood pres-
sure and risk of cardiovascular events (p for interaction=0.042) (table 3 and figure 1). In 
participants without a history of cardiovascular disease, DBP was marginally significant 
associated with an increased event risk (HR (95%) per 10 mmHg increase in DBP 1.08 
(0.99; 1.18), p-value=0.07), whereas in participants with a history of cardiovascular disease 
higher DBP was associated with a decreased risk of cardiovascular events (HR (95%) per 10 
mmHg increase in DBP 0.92 (0.85; 0.99, p-value=0.018). Associations were independent 
of potential confounders, including classical cardiovascular risk factors.
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Abbreviations: HR, Hazard Ratio; CI, confidence interval. *p-value <0.05 1value represents the change in log-hazard 
per 10 mmHg increase in DBP. Sociodemographic factors included sex, age, country and treatment during follow-up 
of the study (pravastatin or placebo). Cardiovascular factors included systolic blood pressure, histories of hypertension, 
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Furthermore, we performed additional analyses in which we explored the association 
between systolic blood pressure with cardiovascular events. Participants with a higher 
systolic blood pressure had an increased risk of cardiovascular events, independent of 
sociodemographic and cardiovascular factors (change in log-hazard per 10 mmHg systolic 
blood pressure (95% CI)=1.04 (1.00;1.08) (supplemental table 1). When stratifying for 
cardiovascular history, the same trend as for diastolic blood pressure was seen, showing 
that higher systolic blood pressure was associated with an increased risk of cardiovascular 
events in participants with and without a previous history of cardiovascular disease (p for 
interaction=0.490) (supplemental table 2). 
Discussion
In this prospective cohort study including 5,804 participants with a mean age of 75 years, 
we show that history of cardiovascular disease modified the relation between diastolic 
blood pressure and cardiovascular event risk: in participants without a history of cardiovas-
cular disease, there was no association between diastolic blood pressure and cardiovascular 
Figure 1. Incidence of cardiovascular events in different diastolic blood pressure groups, stratified by cardiovas-
cular history. Data represent point estimates of incidence (in percentage) of cardiovascular events. 
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events, whereas participants with a history of cardiovascular disease showed a decreased 
risk of cardiovascular events with higher diastolic blood pressure.
Previous studies that showed an association between high diastolic blood pressure and de-
creased cardiovascular risk have predominantly been performed in frail older populations 
in which all participants suffered from cardiovascular disease.(1-3, 5, 7, 9-11) Only few 
have studied whether biological age might determine the association between diastolic 
blood pressure and worse outcomes.(6, 8, 17) Recently, a population-based cohort study 
including 4,057 people investigated if the association of late-life blood pressure with brain 
atrophy and brain functioning differed in people with and without chronic hypertension. 
They found that in participants with a history of midlife hypertension, lower late-life 
diastolic blood pressure was associated with increased brain atrophy and worse cognitive 
function.(17) Furthermore, two prospective studies including 2340 and 1466 participants 
showed that the association of blood pressure with mortality risk was higher in biologically 
older people, defined as those with decreased psychical and cognitive function.(6, 8) To 
our knowledge, we are the first to investigate whether cardiovascular history as a proxy of 
vascular impairment could modulate the association between low diastolic blood pressure 
and cardiovascular risk in older people. 
There are several pathophysiological mechanisms that can explain our finding that his-
tory of cardiovascular disease modified the relation between diastolic blood pressure and 
cardiovascular event risk. First, low diastolic blood pressure might be a reflection of dete-
riorating health status, leading to increased cardiovascular events and mortality.(18) Previ-
ous studies have demonstrated that a decreasing trend in blood pressure independently 
predicts cardiovascular events and mortality in older people.(4, 7) This is in line with results 
from a community based study of 835 subjects of 85 years and older, showing that the 
relation of low blood pressure with mortality disappeared after adjusting for indicators of 
poor health.(1) Indeed, our results demonstrate that risk factors for cardiovascular events 
and mortality such as older age, history of myocardial infarction and smoking status were 
more present in participants with lower diastolic blood pressure. However, adjusting our 
results for these indicators did not essentially change our findings. A second explanation 
is that both low diastolic blood pressure and cardiovascular events share a common cause, 
which most likely would be aging of the arterial system including atherosclerosis. Previ-
ous studies showed that progression of atherosclerosis is accompanied by a decrease in 
diastolic blood pressure.(19, 20) Instead of being causally related, low diastolic blood pres-
sure might therefore be a reflection of widespread atherosclerosis, which itself associates 
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2
27
with increased risk of cardiovascular disease and mortality.(21) However, this might not be 
true for the population under study since pulse pressure, which reflects arterial aging and 
atherosclerosis best, was lower instead of higher in participants with low diastolic blood 
pressure.(22) Finally, there might be a causal relation between low diastolic blood pressure 
and cardiovascular events and mortality rates. In this scenario, low diastolic blood pressure, 
which is an important contributor of the perfusion pressure of an organ, might predispose 
to vascular hypoperfusion of vital organs, particularly in people who already suffer from 
increased arterial stiffness.(23, 24) It has been shown that diastolic blood pressure is more 
important than systolic blood pressure with respect to adequate perfusion of an organ.
(5) Therefore, low perfusion pressure could also explain why we did not find a consistent 
association between systolic blood pressure with cardiovascular events. Furthermore, it 
suggests that excessive reduction of diastolic blood pressure in these people should be 
avoided, and has an experimental underpinning.(5) 
Major strengths of the current study include the large sample size and the detailed moni-
toring during a mean follow-up period of 3.2 years. Furthermore, because of the inclusion 
criteria of PROSPER, all participants had cardiovascular disease or were at risk thereof, 
which provided us the unique opportunity to investigate the hypothesis whether people 
with a vascular impairment would suffer more from a lower diastolic blood pressure. How-
ever, this study also has several weaknesses. First, the study population consisted of older 
participants at risk of cardiovascular diseases with relatively preserved cognitive function 
(MMSE≥24 points), which might limit the extrapolation of our findings to the elderly popu-
lation in general. A second limitation is that the design of the study is observational. Future 
trials investigating whether people with a cardiovascular history benefit from discontinua-
tion of blood pressure lowering therapy are needed to provide definite answers.(25) 
In conclusion, our study demonstrates that the association of diastolic blood pressure with 
cardiovascular events in older people varies upon previous cardiovascular history, showing 
that in participants with cardiovascular history higher diastolic blood pressure associates 
with a decreased risk of cardiovascular events. Randomized controlled trials are needed to 
investigate whether increasing diastolic blood pressure levels by discontinuation of blood 
pressure lowering therapy will lead to less recurrent events in people with a cardiovascular 
history. Eventually, this may result in moving from a ‘one size fits all’ concept of achieving 
normal blood pressure to an individualized approach and specific guidelines in blood pres-
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Background Visit-to-visit blood pressure variability has been related to cerebrovascular 
damage. The aim of this study was to assess the association between visit-to-visit blood 
pressure variability and cognitive function in older subjects. 
 
Methods We included 5,461 subjects from the PROspective Study of Pravastatin in the 
Elderly at Risk (PROSPER) study. Blood pressure was measured every three months during 
an average period of 3.2 years. Blood pressure variability was defined as the standard 
deviation of visit-to-visit blood pressure measurements. Four domains of cognitive func-
tion including selective attention, processing speed, immediate and delayed memory were 
assessed and a compound cognitive score was computed by averaging the four standard-
ized z-scores. In an MRI substudy of 553 participants, structural brain volumes, cerebral 
microbleeds, infarcts, and white matter hyperintensities were measured. 
 
Results Participants with higher visit-to-visit variability in systolic blood pressure had worse 
performance on all cognitive tests: attention (mean difference high versus low thirds) 3.08 
seconds (95% confidence interval (CI) 0.85 to 5.31), processing speed -1.16 digits coded 
(95% CI-1.69 to -0.63), immediate memory -0.27 pictures remembered (95% CI -0.41 to 
-.13), and delayed memory -0.30 pictures remembered (95% CI -0.49 to -0.11). Further-
more, higher variability in both systolic and diastolic blood pressure was associated with 
lower hippocampal volume and cortical infarcts, and higher variability in diastolic blood 
pressure was associated with cerebral microbleeds (all p-values<0.05). All associations 
were adjusted for average blood pressure and cardiovascular risk factors. 
 
Conclusion Higher visit-to-visit variability in blood pressure independent of average blood 
pressure was associated with impaired cognitive function in old age.




Visit-to-visit variability in blood pressure independent of average blood pressure is related 
to cerebrovascular damage.(1) It has been shown that higher blood pressure variability 
increases the risk of stroke and that antihypertensives, which decrease both variability in 
blood pressure and mean blood pressure, more effectively reduce the risk of stroke.(2) In 
addition, observational studies have shown associations of variability in blood pressure, 
independent of average blood pressure, with white matter hyperintensities, carotid artery 
intima media thickness, and atherosclerosis in older people (≥55 years).(3-5)
The relation between increased variability in blood pressure and end organ damage is 
well established.(6) Recent evidence indicates that higher visit-to-visit variability is linked 
with microvascular damage, endothelial injury, and disturbances in vascular smooth muscle 
functioning.(7, 8) Indicators of cerebral small vessel disease, including white matter hyper-
intensities, cortical microinfarcts, and cerebral microbleeds are implicated in the pathogen-
esis of cognitive impairment.(9-11) Several pathological, observational, and experimental 
studies have shown that disruption of the blood-brain barrier due to microvascular dam-
age results in neuronal injury and accelerates neuronal loss and brain atrophy.(12) Hence 
higher variability in blood pressure might potentially lead to cognitive impairment through 
changes in the brain structures and development of cerebral small vessel disease.
We investigated the association of variability in blood pressure between visits independent 
of average blood pressure with cognitive function in older participants (>70 years) at high 
risk of cardiovascular disease. Additionally, we investigated possible explanations behind 
this association in a magnetic resonance imaging substudy.
Methods
Study design and participants
The data in this study were obtained from PROSPER (The PROspective Study of Pravastatin 
in the Elderly at Risk), a randomized, double blind, placebo controlled trial designed to 
investigate the effect of pravastatin in the prevention of vascular events in elderly people 
with pre-existing, or risk factors for, cardiovascular disease. This trial included 5,804 people 
aged 70-82 years who were enrolled from three collaborating centers in Ireland, Scotland, 
and the Netherlands. Approximately 50% of the participants showed evidence of car-
diovascular disease, including stable angina, intermittent claudication, stroke (the type, 
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hemorrhagic or ischemic, was unknown), transient ischemic attack, myocardial infarction, 
and vascular surgery. The rest of the participants had one or more major cardiovascular 
risk factors, defined as hypertension, cigarette smoking, or diabetes mellitus. The primary 
outcome of the PROSPER study was the combined endpoint of definite or suspected death 
from coronary heart disease, non-fatal myocardial infarction, and fatal or non-fatal stroke 
during a mean follow-up period of 3.2 years. In the present study we included 5461 
participants for whom data on variability in blood pressure and cognitive function were 
available. Additionally, participants from the Netherlands were invited to participate in an 
MRI substudy. Participants were included from both the pravastatin and placebo groups as 
we previously reported that treatment with pravastatin did not influence cognitive func-
tion, structural brain volumes, or indicators of cerebral small vessel disease.(13-15) 
Blood pressure measurements
We measured systolic and diastolic blood pressure at baseline and every three months. 
Blood pressure was measured with participants in the sitting position and using a fully 
automatic electronic sphygmomanometer (Omron M4, Kyoto, Japan). All measurements 
were performed in the same clinical setting. In the analyses we used the average values of 
these blood pressure measurements. We defined visit-to-visit variability in blood pressure 
as the standard deviation of blood pressure measurements during the study period. We 
report the variability in blood pressure using only the standard deviation. Variance and 
coefficient of variation, which are two other measures of variability, are strongly correlated 
with the standard deviation (supplemental table 1) and they showed similar associations 
with cognitive and magnetic resonance imaging outcomes (data not shown).
Cognitive function
The Mini-Mental State Examination (MMSE) was used to evaluate global cognitive function 
at baseline; to exclude participants with poor cognitive function at baseline we used a cut-
off score of 24 points or more (out of 30) as an inclusion criterion. In the present study we 
used data on cognitive function assessed at the end of the study, after a mean follow-up 
of 3.2 years, by a cognitive test battery consisting of four different tests. The Stroop colour 
and word test was used to assess selective attention and reaction time. The participants 
were asked to read the name of a colour, which appeared in a colour different from that 
being named. The outcome variable was the total number of seconds to complete the 
test; a higher score indicating worse performance. General cognitive speed was tested 
by the letter-digit coding test. The participants had to match certain digits with letters 
according to a provided key. The outcome variable was the total number of correct entries 
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in 60 seconds, with higher scores indicating better performance. The picture-word learning 
test was used to assess immediate and delayed memory. The participants were shown 15 
pictures and were then asked to recall as many pictures as possible in three trials. After 20 
minutes they were asked to repeat the test to measure their delayed recall. The outcome 
variable was the accumulated number of correct recalled pictures, immediately and after 
20 minutes, with higher scores indicating better performance. A detailed description of the 
cognitive tests and the procedures has been published previously.(16) 
Magnetic resonance imaging substudy
Overall, 646 of the 1100 Dutch participants in the PROSPER study consented to participate 
in the magnetic resonance imaging substudy. Forty of the 646 original study participants 
died during the follow-up period. Magnetic resonance imaging was performed at the end 
of the follow-up period in the remaining 606 participants. Data on visit-to-visit variability in 
blood pressure and magnetic resonance imaging were available for 553 participants. Details 
of individually magnetic resonance imaging scanning have been published previously.(13)
All imaging was performed on a magnetic resonance system operating at a field strength 
of 1.5 Tesla (Philips Medical Systems, Best, Netherlands). We used the SIENAX technique to 
calculate grey and white matter volumes. In short, SIENAX starts by extracting brain and skull 
images from input data for the whole head. The brain image is then affine registered to Mon-
treal Neurological Institute 152 space (by using the skull image to determine the registration 
scaling), done primarily to obtain the volumetric scaling factor to be used as normalisation 
for head size. Next we carried out tissue type segmentation with partial volume estimation 
to calculate the total volume of brain tissue (including separate estimates of volumes of 
grey matter, white matter, peripheral grey matter, and ventricular cerebrospinal fluid).(17) 
The algorithm FIRST (the Oxford Centre for Functional MRI of the Brain’s (FMRIB) integrated 
registration and segmentation tool) was applied to estimate the volume of hippocampus. 
In addition, we estimated the volume of six other subcortical regions, including nucleus 
accumbens, globus pallidus, amygdala, putamen, caudate nucleus, and thalamus. FIRST 
is part of FSL (FMRIB’s software library) and performs both registration and segmentation 
of the mentioned subcortical regions.(18) To assess cerebral microbleeds, two experienced 
raters blinded to the participants’ clinical history read all the magnetic resonance imaging 
scans in consensus. Cerebral microbleeds were defined as focal areas of signal loss on T2 
weighted gradient echo pulse sequence (“blooming effect”) that were invisible or smaller on 
T2 weighted magnetic resonance imaging.(19) For each participant we recorded the number 
and location (cortical, subcortical, and infratentorial) of the cerebral microbleeds. Segmenta-
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tion of white matter hyperintensities volume was performed automatically using software for 
Neuro-Image Processing in Experimental Research (SNIPER), an in-house developed program 
for image processing.(20) This segmentation was based on the T2-weighted and fluid at-
tenuated inversion recovery (FLAIR) images. Cerebral infarcts were defined as parenchymal 
defects seen on FLAIR images with the same signal intensity as cerebrospinal fluid and a 
surrounding rim of high signal intensity following a vascular distribution.
Personal and clinical characteristics
We recorded the personal, medical, and anthropometric data of the participants at baseline. 
A fasting venous blood sample was taken for biochemical and hematological assessment. 
Western blotting was used on the plasma samples to determine apolipoprotein E epsilon 
2/3/4 phenotype.(21) 
Statistical analysis
Characteristics of the study participants are reported as mean (standard deviation) for 
continuous variables and frequency (percentage) for categorical variables. We used 
Pearson’s correlation coefficient to calculate the correlation between variability in blood 
pressure and average blood pressure. Linear regression models were used to assess the 
association of variability in blood pressure and average blood pressure with cognitive func-
tion. Dependent variables were the mean scores of the cognitive tests. In the tables these 
scores are presented in thirds of systolic and diastolic blood pressure and blood pressure 
variability. In the magnetic resonance imaging substudy, we used logistic regression models 
to estimate the odds ratio and 95% confidence interval of the presence of microbleeds or 
infarcts in different thirds of blood pressure variability as well as average blood pressure. 
We used multivariable linear regression models to test the association between blood pres-
sure variability and average blood pressure with volume of white matter hyperintensities 
and structural brain volumes. P-values in all the analyses were calculated using systolic and 
diastolic blood pressure variability as continuous variables.
We performed our analyses in three steps. In the first step, we carried out crude analyses, 
in which we only adjusted for cognitive test version where appropriate. In the second step, 
we added age, sex, education, and country as covariates to investigate the potential influ-
ence of these factors on the associations (model 1). In the final model (model 2), we further 
adjusted the analyses for the following potential confounders: cardiovascular diseases and 
risk factors (history of vascular disease, history of hypertension, history of diabetes mellitus, 
smoking status, cholesterol levels, body mass index), average blood pressure, statin treat-
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ment, and apolipoprotein E genotype. We adjusted the analyses of systolic blood pressure 
variability with cognitive function and magnetic resonance imaging outcomes for average 
systolic blood pressure. The analyses of variability in diastolic blood pressure with cognitive 
function and magnetic resonance imaging outcomes were adjusted for average diastolic 
blood pressure. Since the associations did not essentially change in different models, results 
of the second model are presented in the manuscript and results from the other models are 
presented in a supplementary file (available on request). All analyses were performed using 
SPSS software (version 20.0.0, SPSS Inc., Chicago, IL). 
Results
Table 1 shows the characteristics of participants in the whole group and in the magnetic 
resonance imaging substudy. Blood pressure was measured in an average number of 12.7 
visits in the whole group and 12.9 visits in the magnetic resonance substudy. Average 
systolic and diastolic blood pressure over the period of blood pressure measurements were 
153.1 mm Hg and 82.5 mm Hg, respectively. The corresponding mean standard deviation 
values during this period were 14.8 mm Hg and 7.1 mm Hg.
There was a weak but significant correlation between average systolic blood pressure and 
standard deviation of systolic blood pressure measurements (r=0.20, p-value<0.001). Simi-
larly, average diastolic blood pressure was weakly but statistically significantly correlated 
with standard deviation of diastolic blood pressure measurements (r=0.12, p-value<0.001). 
Table 2 shows the association of visit-to-visit variability in systolic and diastolic blood pres-
sure with cognitive function. Higher variability was associated with worse performance 
on the Stroop test (both p-values<0.001), letter-digit coding test (both p-values<0.001), 
immediate picture-word learning test (both p-values<0.001), and delayed picture-word 
learning test (both p-values=0.001). All associations were independent of average blood 
pressure and cardiovascular diseases and risk factors, as all analyses were adjusted for 
these factors. The figure presents the mean cognitive scores (95% confidence intervals) 
in each third of systolic and diastolic blood pressure variability. Data on the association 
of blood pressure variability with cognitive function from crude and minimally adjusted 
models are shown in the supplemental tables 2 and 3. Furthermore, we found a significant 
association of higher average systolic and diastolic blood pressure with worse performance 
in different domains of cognitive function (all p-values<0.05), except for the association 
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between higher average systolic blood pressure and performance on the picture-word 
learning tests (p-values>0.05) (supplementary table 4).






Number of visits, mean (SD) 12.7 (2.4) 12.9 (1.5)
Age, years, mean (SD) 75.3 (3.3) 74.9 (3.2)
Female, n (%) 2822 (51.7) 241 (43.6)
Age left school, years, mean (SD) 15.1 (2.1) 15.5 (2.9)
Vascular risk factors
History of hypertension, n (%) 3399 (62.2) 341 (63.1)
History of diabetes mellitus, n (%) 576 (10.5) 91 (16.5)
History of stroke or TIA, n (%) 606 (11.1) 89 (16.1)
History of myocardial infarction, n (%) 714 (13.1) 67 (12.1)
History of vascular disease, n (%) 2404 (44.0) 240 (43.4)
Current smoker, n (%) 1433 (26.2) 115 (20.8)
Body mass index , kg/m2, mean (SD) 26.9 (4.2) 26.7 (3.6)
Total cholesterol, mmol/L, mean (SD) 5.7 (0.9) 5.7 (0.8)
Blood pressure, mean (SD)
Systolic blood pressure, mm Hg* 153.1 (16.1) 156.1 (16.4)
Diastolic blood pressure, mm Hg * 82.5 (7.5) 85.1 (7.3)
Variability in systolic blood pressure, mm Hg** 14.8 (5.0) 13.9 (4.6)
Variability in diastolic blood pressure, mm Hg** 7.1 (2.9) 7.4 (2.3)
Cognitive function, mean (SD)***
Stroop test score, seconds 69.4 (31.6) 56.9 (23.3)
Letter-Digit Coding test score, digits coded 21.8 (8.0) 26.3 (7.4)
PLTi score, pictures remembered 9.2 (2.2) 10.1 (2.2)
PLTd score, pictures remembered 9.8 (3.1) 11.1 (3.0)
MRI features
Grey matter, ml, mean (SD) --- 590 (44)
White matter, ml, mean (SD) --- 768 (38)
Hippocampus, ml, mean (SD) --- 7.5 (1.1)
Micro-bleeds, n (%) --- 124 (24.0)
Infarcts, n (%) --- 180 (33.6)
Cortical --- 65 (12.1)
Lacunar --- 112 (21.0)
WMH volume, ml, mean (SD) --- 7.2 (1.1)
Abbreviations: SD, standard deviation; n, number; TIA, transient ischemic attack; PLTi, Picture-Word Learning Test im-
mediate; PLTd, Picture-Word Learning Test delayed; WMH, white matter hyperintensity. * defined as the mean of all 
blood pressure measurements during follow-up. ** defined as the standard deviation of all blood pressure measure-
ments during follow-up. *** defined as the cognitive test score at the end of follow-up.  
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Table 3 shows the association of visit-to-visit variability in systolic and diastolic blood 
pressure with structural brain volumes. Higher variability was associated with lower hip-
pocampal volume (both p-values=0.01). There was no association between blood pressure 
variability and volume of the other brain structures (all p-values>0.05), except for the 
association between higher variability in systolic blood pressure and lower amygdala and 
putamen volumes (both p-values=0.04). Analyses were adjusted for average systolic and 
diastolic blood pressures, which themselves were not associated with structural brain 
volumes (all p-values>0.05) (supplemental table 5).
Table 2. Cognitive function in thirds of visit-to-visit blood pressure variability









Range of SD, mm Hg 0.7-12.2 12.3-16.2 16.3-64.4
Stroop, seconds 68.46 (0.79) 68.75 (0.79) 71.54 (0.82) <0.001
LDCT, digits coded 22.40 (0.19) 21.82 (0.19) 21.24 (0.19) <0.001
PLTi, pictures remembered 9.37 (0.05) 9.28 (0.05) 9.10 (0.05) <0.001
PLTd, pictures remembered 10.00 (0.07) 9.89 (0.07) 9.70 (0.08) 0.001
Diastolic blood pressure
Range of SD, mm Hg 0-6.5 6.6-8.5 8.6-33.1
Stroop, seconds 68.28 (0.79) 68.89 (0.79) 71.34 (0.80) <0.001
LDCT, digits coded 22.35 (0.19) 21.93 (0.19) 21.27 (0.19) <0.001
PLTi, pictures remembered 9.41 (0.05) 9.22 (0.05) 9.13 (0.05) <0.001
PLTd, pictures remembered 10.01 (0.07) 9.88 (0.07) 9.74 (0.07) 0.001
Abbreviations: SD, standard deviation; n, number; LDCT, Letter-Digit Coding test; PLTi, Picture-Word Learning Test 
immediate; PLTd, Picture-Word Learning Test delayed. Data are adjusted values of the mean (standard error) of each 
cognitive function test. Adjustments were made for age, sex, body mass index, Statin treatment, apoE genotype, 
country, education, test version where appropriate, smoking, cholesterol levels, history of vascular diseases, history of 
hypertension, history of diabetes mellitus, and average blood pressure measures. 
Table 3. Structural brain volumes in three groups of visit-to-visit blood pressure variability
Three groups of visit-to-visit blood pressure variability
P-valueLow Middle High
Systolic blood pressure (n=194) (n=210) (n=149)
Range of SD, mm Hg 0.7-12.2 12.3-16.2 16.3-64.4
Grey matter 593 (3) 590 (3) 589 (3) 0.21
White matter 770 (3) 770 (3) 765 (3) 0.19
Hippocampus 7.6 (0.07) 7.6 (0.07) 7.4 (0.08) 0.01
Diastolic blood pressure (n=178) (n=184) (n=191)
Range of SD, mm Hg 0-6.5 6.6-8.5 8.6-33.1
Grey matter 591 (3) 594 (3) 587 (3) 0.18
White matter 768 (3) 772 (3) 764 (3) 0.62
Hippocampus 7.6 (0.07) 7.5 (0.07) 7.4 (0.07) 0.01
Data are structural brain volumes presented in mean (standard error) ml. Analyses were adjusted for age, sex, body 
mass index, Statin treatment, smoking, cholesterol level, history of vascular diseases, history of hypertension, history of 
diabetes mellitus, and average blood pressure measures.
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Table 4 shows the association between visit-to-visit variability in blood pressure and cere-
bral microbleeds, infarcts, and white matter hyperintensities. Higher variability in systolic 
and diastolic blood pressure was associated with a higher risk of cortical infarcts (both 
p-values=0.02). Prevalence of cortical infarcts in participants with low, middle, and high 
variability in systolic blood pressure was 9.2%, 12.0%, and 16.2%, respectively. Prevalence 
of cortical infarcts in participants with low, middle, and high variability in diastolic blood 
pressure was 7.9%, 13.3%, and 16.2%, respectively. Furthermore, higher variability in 
diastolic blood pressure was associated with a higher risk of all types of microbleeds (p-
value=0.01) as well as subcortical microbleeds (p-value=0.004). Prevalence of microbleeds 
in participants with low, middle, and high variability in systolic blood pressure was 21.2%, 
23.9%, and 28.4%, respectively. Prevalence of cortical infarcts in participants with low, 
middle, and high variability in diastolic blood pressure was 17.8%, 27.5%, and 28.9%, 
respectively. Variability in systolic and diastolic blood pressure was not associated with 
white matter hyperintensities (both p-values>0.05). We found no association of average 
systolic and diastolic blood pressure with cerebral microbleeds, infarcts, and white matter 
hyperintensities (all p-values>0.05) (supplemental table 6).
Table 4. Microbleeds, infarcts and white matter hyperintensities in three groups of visit-to-visit blood pressure 
variability
Three groups of visit-to-visit blood pressure variability
Low Middle High P-value
Systolic blood pressure (n=207) (n=191) (n=137)
Range of SD, mm Hg 0.7-12.2 12.3-16.2 16.3-64.4
Microbleeds, OR (95% CI) 1 (ref) 1.13 (0.69-1.85) 1.30 (0.77-2.21) 0.39
Infarcts, OR (95% CI) 1 (ref) 0.95 (0.61-1.48) 1.26 (0.78-2.04) 0.40
Cortical 1 (ref) 1.34 (0.68-2.64) 2.22 (1.09-4.54) 0.02
Lacunar 1 (ref) 0.79 (0.48-1.31) 0.84 (0.48-1.46) 0.97
WMH volume, ml, mean (SE) 8.12 (1.02) 7.34 (1.08) 7.79 (1.19) 0.98
Diastolic blood pressure (n= 215) (n= 166) (n= 154)
Range of SD, mm Hg 0-6.5 6.6-8.5 8.6-33.1
Microbleeds, OR (95% CI) 1 (ref) 1.75 (1.05-2.91) 1.77 (1.06-2.96) 0.01
Infarcts, OR (95% CI) 1 (ref) 0.99 (0.63-1.56) 1.32 (0.84-2.06) 0.43
Cortical 1 (ref) 1.87 (0.93-3.76) 2.19 (1.10-4.37) 0.02
Lacunar 1 (ref) 0.95 (0.57-1.60) 1.17 (0.70-1.95) 0.75
WMH volume, ml, mean (SE) 7.65 (1.05) 8.27 (1.11) 7.93 (1.10) 0.55
Abbreviations: SD, standard deviation; n, number; OR, odds ratio; CI, confidence interval; WMH, white matter hy-
perintensity; SE, standard error.  Analyses were adjusted for sex, age, body mass index, Statin treatment, smoking, 
cholesterol levels, history of vascular diseases, history of hypertension, history of diabetes mellitus, and average blood 
pressure measures. Data for microbleeds, infarcts and white matter hyperintensities were available for 535 participants.
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Stroop test, Letter-Digit Coding Test (LDCT), immediate Picture-Word Learning Test (PLTi) and delayed Picture-Word Learning 
Test (PLTd) scores in low, middle and high thirds of systolic and diastolic visit-to-visit blood pressure variability. Bars represent
mean and 95% confidence interval. All analyses were adjusted for age, sex, body mass index, Statin treatment, apo E 
genotype, country, education, test version where  appropriate, smoking, cholesterol level, history of vascular diseases, history of 
hypertension, history of diabetes mellitus, and average blood pressure measures.
Figure 1. Cognitive function in thirds of visit-to-visit blood pressure variability       
Stroop test, Letter-Digit Coding Test (LDCT), immediate Picture-Word Learning Test (PLTi) and delayed Picture-Word 
Learning Test (PLTd) scores in low, middle and high thirds of systolic and diastolic visit-to-visit blood pressure variability. 
Bars represent mean and 95% confidence interval. All analyses were adjusted for age, sex, body mass index, Statin 
treatment, apo E genotype, country, education, test version where  appropriate, smoking, cholesterol level, history of 
vascular diseases  f hyp rtension, history of diabetes mellitu , and average blood pressure measures
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We performed four sensitivity analyses to explore whether the association of visit-to-visit 
variability in blood pressure with the studied outcomes could be affected by participants 
with a history of clinical stroke or transient ischemic attack (n=606) and cardiovascular 
disease (n=2404), participants with new or a change in antihypertensive therapy during 
the study period (n=2733), participants who developed vascular events (n=872) or arrhyth-
mia (n=506) during the study period, and participants with a high average blood pressure 
(defined as average systolic blood pressure of ≥140 mm Hg and diastolic blood pressure of 
≥80 mm Hg during the study period) (n=830). These sensitivity analyses showed that the 
results did not materially change. In an overall sensitivity analysis we excluded all partici-
pants with the aforementioned conditions (n=4654) and the results remained essentially 
unchanged (data not shown).
Discussion
Higher visit-to-visit variability in systolic and diastolic blood pressure was associated with 
worse performance in different domains of cognitive function and lower hippocampal 
volume and risk of cortical infarcts. Higher variability in diastolic blood pressure was as-
sociated with risk of cerebral microbleeds. These associations were independent of various 
cardiovascular risk factors, in particular average systolic and diastolic blood pressures.
 
Although hypertension is a well-established risk factor for cardiovascular diseases, increas-
ing evidence indicates that the predictive value of conventional blood pressure measure-
ment for cardiovascular diseases attenuates with increasing age.(22-24) Recent studies 
have shown that higher visit-to-visit variability in blood pressure increases the risk of car-
diovascular events, stroke, and carotid artery atherosclerosis in older people, independent 
of average blood pressure.(1, 24-26) Given the link between neurovascular dysfunction 
and cognitive impairment, a recent study on 201 elderly participants (mean age 79.9 years) 
at high risk of cardiovascular disease showed that high visit-to-visit variability in blood 
pressure during 12 months was associated with worse performance in the mini-mental 
state examination and global deterioration scale.(27, 28) Consistent with this finding, 
by using a population of over 5000 participants and over three years of blood pressure 
measurements, we showed that high visit-to-visit variability in both systolic and diastolic 
blood pressure was associated with worse performance in different domains of cognitive 
function, including selective attention, processing speed, immediate verbal memory, and 
delayed verbal memory. 
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The magnitude of associations in this study, reflected as differences in cognitive scores 
between top and bottom thirds of variability in systolic and diastolic blood pressure, are 
comparable with the observed differences in cognitive function between groups of apo-
lipoprotein E genotype on cognitive function.(29) The apolipoprotein E4 genotype is a 
well-recognized risk factor for the development of dementia in later life and it has been 
shown that people who carry this risk factor have a four times higher risk of developing late 
onset Alzheimer`s disease.(30) Similar differences in cognitive test scores in apolipoprotein 
E groups and variability in blood pressure implies that the observed associations can be 
considered clinically relevant.
Different explanations can be proposed for the observed association between high visit-
to-visit variability in blood pressure and impaired cognitive function. Firstly, both blood 
pressure variability and cognitive impairment could stem from a common cause, without 
themselves being causally related. Cardiovascular risk factors are the most likely candidate.
(31) Nevertheless, we reported our analyses adjusted for different cardiovascular risk fac-
tors and we performed a sensitivity analysis, by separately excluding those with a history 
of cardiovascular diseases. This did not change our estimates, although we accept that 
residual confounding could remain from unmeasured risk factors for cardiovascular dis-
ease. As a second explanation, high visit-to-visit variability in blood pressure might reflect 
a long term hemodynamic instability in the systemic circulation that puts stress on the 
vascular endothelium.(7, 32) This hemodynamic stress may lead to endothelial dysfunction 
and micro-vascular damage with consequent alterations in brain structure and function.
(33) Thirdly, exaggerated fluctuations in systemic blood pressure could result in repeated 
episodes of cerebral hypoperfusion causing neuronal injury and cell death, particularly in 
vulnerable brain regions such as the hippocampus.(4) In line with latter explanations, we 
found that higher visit-to-visit variability in blood pressure is related to lower hippocampal 
volume and the presence of cerebral microbleeds and cortical infarcts. Given the well 
described association of hippocampal atrophy and cerebral small vessel disease with cogni-
tive impairment, our findings may suggest that decreased hippocampal volume, cerebral 
microbleeds, and cortical infarcts are potential pathogenic mechanisms behind the associa-
tion between variability in blood pressure and cognitive impairment.(10, 34) 
Current evidence on the association of blood pressure variability with structural brain 
damage and cerebral small vessel disease mainly comes from studies that focused on 
ambulatory blood pressure rather than visit-to-visit variability. These studies showed that 
higher variability in ambulatory blood pressure is associated with brain atrophy and white 
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matter lesions.(35-37) In the present study, we only observed the association of visit-to-visit 
variability in blood pressure with lower hippocampal volume, cerebral microbleeds, and 
cortical infarcts. This might imply that different measures of blood pressure variability carry 
different predictive values for brain outcomes.(24) Data on the association between visit-
to-visit variability and manifestations of small vessel diseases are scarce. Consistent with 
our findings, a recent study showed that higher visit-to-visit variability in blood pressure 
in people with a history of ischemic stroke was associated with progression of cerebral 
microbleeds but not with white matter lesions.(38) It is, however, still unclear whether 
higher variability in blood pressure is a cause or consequence of brain disease. It has been 
suggested that higher variability itself could originate from previously established brain 
diseases disturbing central autonomic control.(39) While clinical trials have shown conflict-
ing findings on the benefit of antihypertensive therapy on reducing the risk of dementia, 
calcium channel blockers, the most effective drug class to reduce variability in blood pres-
sure, showed significant efficacy in lowering the risk of vascular cognitive impairment.(40, 
41) This might highlight potential clinical implications of agents reducing blood pressure 
variability in lowering the risk of brain vascular disease and cognitive impairment in old 
age. Collectively, we are not able to make a causal inference from our observation, and 
future long term investigations are warranted to examine whether strategies to reduce 
variability in blood pressure can effectively decrease the risk of cognitive impairment as 
well as of brain vascular disease.
The major strengths of this study include a large sample size and application of an ex-
tended standardized cognitive test battery to assess cognitive function. In addition, avail-
ability of neuroimaging data provided us with a unique opportunity to investigate potential 
biological pathways linked to the association between variability in blood pressure and 
cognitive function. However, this study has certain limitations. Firstly, we included elderly 
participants at risk of cardiovascular diseases with relatively preserved cognitive function 
(mini-mental state examination ≥24 points), which might limit the extrapolation of our 
findings to a general elderly population. However, this restriction has possibly resulted in 
a homogeneous study population who are among the main target groups for preventing 
cognitive decline.(42) Secondly, the outcomes of this study were evaluated at one time 
point, and long term longitudinal studies are needed to test whether lowering variability in 
blood pressure could lead to decelerated cognitive decline and lower the burden of brain 
diseases. Thirdly, owing to the limited number of participants in the magnetic resonance 
imaging substudy, we had limited power in several outcome measures. This means that 
the absence of significant associations for several outcome measures should be interpreted 
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with caution. There are reports indicating that higher visit-to-visit variability in blood pres-
sure is related to a higher risk of stroke and cerebrovascular damage, however, the exact 
mechanisms behind these associations are still unclear.(1) This problem needs to be ad-
dressed in future magnetic resonance imaging studies with larger number of participants. 
Fourthly, although we adjusted our analyses for different potential confounding factors, 
some other confounders may exist that we did not consider in our analyses. Future studies 
investigating the determinants of visit-to-visit variability in blood pressure might help to 
understand better the association between variability in blood pressure and neurocognitive 
outcomes.
In conclusion, our findings suggest that higher visit-to-visit variability in blood pressure 
independent of average blood pressure is associated with worse cognitive performance in 
older people at high risk of cardiovascular disease. Changes in hippocampal volume and 
occurrence of cortical infarcts and cerebral microbleeds might be candidate pathogenic 
mechanisms behind this association. This observation merits further interventional studies 
to determine whether reducing variability in blood pressure can decrease the risk of cogni-
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Background Visit-to-visit blood pressure variability is associated with cognitive impair-
ment. We assessed to what extent the association between blood pressure variability and 
cognitive impairment is mediated by the association of blood pressure lowering mediation 
with both blood pressure variability and cognition.
Methods We studied 5,606 participants from the PROspective Study of Pravastatin in the 
Elderly at Risk. Blood pressure was measured every three months during 3.2 years; blood 
pressure variability was defined as the standard deviation of blood pressure measurements 
during follow up. Cognitive function was assessed at baseline and during follow-up using 
the Stroop test, Letter-Digit Coding test, immediate and delayed Picture-Word Learning 
tests. Multivariate regression models were used with and without adjustments for blood 
pressure lowering medication to calculate the percentage to which blood pressure lower-
ing medication mediated the association between blood pressure variability and cognition.
Results Participants taking calcium-antagonists had a higher score in baseline Letter-Digit 
Coding test (mean difference (95% confidence interval (CI) 0.45 (0.06; 0.88). Participants 
taking beta-blockers had a steeper decline in Stroop test (additional change per year (95% 
CI) 0.40 (0.09; 0.70) and Letter-Digit Coding test (0.08 (-0.15; -0.02)). Furthermore, a 
steeper decline in Stroop test was found in participants taking RAS-inhibitors (0.50 (0.16; 
0.85). Systolic blood pressure variability was higher in participants taking beta-blockers and 
RAS-inhibitors (mean difference in systolic blood pressure variability in mmHg (95% CI) 
0.75 (0.45; 1.04) and 1.37 (1.04; 1.71) respectively). Participants taking diuretics, calcium 
antagonists and RAS-inhibitors had a higher diastolic blood pressure variability (mean dif-
ference in diastolic BP variability in mmHg (95% CI) 0.27 (0.04; 0.49), 0.37 (0.12; 0.62) 
and 0.65 (0.37; 0.93) SD, respectively). Beta estimates remained essentially the same when 
we adjusted for blood pressure lowering medication in the association of blood pressure 
variability with cognitive function. 
Conclusion The association between blood pressure variability and cognitive impairment 
was not mediated by blood pressure lowering medication.




Visit-to-visit blood pressure variability independent of average blood pressure is associated 
with higher cardiovascular risk in older adults. Several observational studies have shown 
that higher levels of blood pressure variability are related with increased risk of stroke, 
coronary events, heart failure hospitalization and cardiovascular and all-cause mortality.
(1-5) Furthermore, blood pressure variability has been associated with white matter hy-
perintensities, intima media thickness and carotid artery atherosclerosis in older adults.
(6-8) Recent evidence has shown that older subjects with higher levels of blood pressure 
variability have worse cognitive function.(9-11) Again, these findings were independent of 
average blood pressure. 
Besides average blood pressure, reducing the variability of blood pressure might therefore 
be of importance. Blood pressure lowering medication may have class-specific effects on 
blood pressure variability, but evidence on the association of blood pressure lowering 
medication with blood pressure variability is limited. A recent meta-analysis of clinical trials 
showed that compared with other drugs, systolic blood pressure variability was reduced 
the most in subjects using calcium-channel blockers and non-loop diuretics; systolic blood 
pressure variability was higher in subjects using angiotensin-converting enzyme (ACE) 
inhibitors and beta-blockers.(12) Besides the effects on blood pressure variability, blood 
pressure lowering medication, especially calcium channel blockers, also seem to have class-
specific effects in decreasing the risk of dementia.(13-16) Therefore, we hypothesized that 
the association between blood pressure variability and cognitive impairment might partially 
be caused by different effects of blood pressure lowering medication on both blood pres-
sure variability and cognitive function. 
We have previously described the association between blood pressure variability and cogni-
tive function within this study population. Now, we evaluated whether the association 
between blood pressure variability and cognitive function could be mediated by blood 
pressure lowering medication.(9) We used data from the PROspective Study of Pravastatin 
in the Elderly at Risk (PROSPER), a multicenter trial including 5,804 participants with a 
mean age of 75 years, who all had repeated measurements of blood pressure and different 





Data in this study were obtained from the Prospective Study of Pravastatin in the Elderly 
at Risk (PROSPER): a randomized, double-blind, placebo-controlled trial designed to in-
vestigate the effect of pravastatin treatment to prevent vascular events in elderly men 
and women with pre-existing cardiovascular disease or risk factors thereof.(17) Primary 
outcome of this trial was the combined endpoint of definite or suspect death from coro-
nary heart disease, non-fatal myocardial infarction and fatal or non-fatal stroke during 
a mean follow-up period of 3.2 years. PROSPER included 5,804 individuals aged 70-82 
years old who were enrolled from three collaborating centers in Ireland, Scotland and 
the Netherlands.(17) In the present study we included 5,606 participants for whom data 
on blood pressure lowering medication and blood pressure variability were available. The 
institutional ethics committees of the three collaborating centers approved the study and 
all participants gave written informed consent.
Blood pressure lowering medication
Information about use and type of blood pressure lowering medication was self-recorded 
at baseline. A research nurse reported change in blood pressure lowering medication dur-
ing every three-monthly study visit. Dosage of blood pressure lowering medication was 
unknown. For the present study, we only investigated participants who used one or more 
of the following classes of blood pressure lowering medication: diuretics, beta-blockers, 
calcium antagonists and renin-angiotensin system (RAS)-inhibitors (including angiotensin-
converting-enzyme and angiotensin-receptor antagonists).
Blood pressure measurements
Blood pressure was measured at baseline and every three months during a mean 3.2 year 
follow-up period. Blood pressure was measured in sitting position using a fully automatic 
electronic sphygmomanometer (Omron M4®). All measurements were performed in the 
same clinical setting. Average blood pressure was calculated for each participant as the 
mean value of all blood pressure measurements during follow-up. Blood pressure vari-
ability was defined as the standard deviation of all blood pressure measurements during 
follow-up for each participant. 




The Mini-Mental State Examination (MMSE) was used to evaluate global cognitive function 
at baseline; a cutoff score of 24 points or more (out of 30) was used as an inclusion crite-
rion to exclude subjects with poor cognitive function at baseline.(18) Cognitive function 
was tested at baseline, after 9, 18, 30 months and at the end of the study by a cognitive 
test battery consisting of four different tests.(18) For the current study, we used data on 
cognitive function assessed at the end of follow-up; to ensure that the determinant (blood 
pressure variability during follow-up) preceded the outcome variable (cognitive function). 
The time point of the measurement at the end of the study varied between 36 months 
and 48 months. The Stroop-Colour-Word-Test was used to test selective attention and 
reaction time of the participants. The participants were asked to read a color name which 
was displayed in a color different from the color it actually names. The outcome parameter 
was total number of seconds to complete the test; a higher score therefore indicates 
worse performance. General cognitive speed was tested by the Letter-Digit Coding Test. 
The participants had to match certain digits with letters according to a provided key. The 
outcome variable was the total number of correct entries in 60 seconds, and therefore 
higher scores represent better performance. The Picture-Word Learning Test was used to 
assess immediate and delayed memory performance. Fifteen pictures were presented at 
the participants, and they were asked to recall as many pictures as possible in three trials. 
After 20 minutes they were asked to repeat the test to measure their delayed recall. The 
outcome parameter is the accumulated number of correct recalled pictures, immediate and 
after 20 minutes. Higher scores thus indicate better performance. A detailed description of 
the cognitive tests and the procedures has been published previously.(18) 
Statistical analyses
In the present study, we compared participants using the specific class of blood pressure 
lowering medication with participants not using this specific medication class. Baseline 
characteristics of the study participants are reported as mean (standard deviation) for 
continuous variables and number (percentage) for categorical variables. We used an inde-
pendent t-test (for continuous variables) and a Chi-square test (for categorical variables) 
to assess whether there was a difference in baseline characteristics between participants 
using a specific medication class compared to participants not using this medication class. 
We first investigated the association between blood pressure lowering medication and 
blood pressure variability by multivariate linear regression models. Independent variables 
were blood pressure lowering medication class; systolic and blood pressure variability were 
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the dependent variables. Second, we assessed the association between blood pressure 
lowering medication and cognitive function at baseline and cognitive decline during 
follow-up. For the baseline associations, we used multivariate linear regression models, 
with class of blood pressure lowering medication as an independent variable and cognitive 
tests as dependent variables. Furthermore, for the association of blood pressure lower-
ing medication with cognitive decline over time,. linear mixed models were used, which 
included class of blood pressure lowering medication, time (in years) and the interaction 
term between class of blood pressure lowering medication and time. We performed our 
analyses according to two different models. In a minimally adjusted model, we adjusted 
our analyses for age, sex and country. In the final model (fully adjusted model), we ad-
ditionally adjusted our analyses for the following potential confounders: study treatment, 
cardiovascular diseases and risk factors (history of vascular disease, history of hypertension, 
history of diabetes mellitus, smoking status, cholesterol levels, body mass index), estimated 
glomerular filtration rate (eGFR), number of blood pressure lowering medications, and 
average blood pressure during follow-up. Concerning the association between blood pres-
sure lowering medication and blood pressure variability, we additionally adjusted for use 
of other blood pressure lowering medications. Furthermore, the analyses between blood 
pressure lowering medication and cognition were adjusted for education (defined as age 
left school). 
In a third statistical analysis, we determined whether blood pressure lowering medication 
mediated the association of blood pressure variability and cognitive function. For this, 
we added class of blood pressure lowering medication to the model which examined the 
association between blood pressure variability and cognitive function. Each class of blood 
pressure lowering medication was first included separately in the analysis; however we 
also included combinations of blood pressure lowering medication and all blood pressure 
lowering medication. We did not incorporate interaction between blood pressure lowering 
medication and blood pressure variability in the model. Finally, we calculated the percent-
age of the association explained by blood pressure lowering medication.(19) We defined a 
percentage of 10% or greater as evidence of potential medication. To account for change 
in blood pressure lowering medication during follow-up, we performed an additional 
sensitivity analysis in which we excluded all participants who changed their blood pressure 
lowering medication during follow-up. 
All analyses were performed using SPSS (version 20.0.0, SPSS Inc., Chicago, IL). 




Out of the 5,804 participants of PROSPER, we excluded 198 participants who had only 
one or two blood pressure measurements during follow-up. This resulted in a final study 
sample of 5,606 participants.
Table 1 shows the baseline characteristics in different classes of blood pressure lowering 
medication. Participants taking RAS-inhibitors had the lowest age and participants taking 
loop diuretics had the highest age at baseline. Prevalence of vascular diseases and risk fac-
tors varied among the groups, most probably reflecting differences in indications for which 
blood pressure lowering medication was prescribed. Systolic blood pressure was lowest 
Table 1. Baseline characteristics in different classes of blood pressure lowering medication 











Age (years) 75.63 (3.41)** 75.29 (3.37) 75.41 (3.28) 75.35 (3.35)
Female, n (%) 1457 (64.3%)** 792 (54.6%)* 684 (48.6%)* 565 (54.7%)*
Country, n (%)
The Netherlands 326 (15.4%)** 321 (22.1%)* 224 (15.9%)** 286 (27.7%)**
Ireland 932 (41.4%)** 538 (37.1%)* 428 (30.4%)** 467 (45.3%)**
Scotland 1008 (44.5%)** 592 (40.8%)* 754 (53.6%)* 279 (27.0%)**
Education (age left school) 15.12 (1.96) 15.15 (2.09) 15.04 (1.92)* 15.28 (2.24)*
Total number of medications 4.29 (2.26)** 4.21 (2.11)** 4.81 (2.29)** 4.47 (2.29)**
Total number of BP measurements during 
follow-up
11.24 (2.83) 11.38 (2.64) 11.22 (2.87) 11.16 (2.74)
Vascular risk factors
History of hypertension, n (%) 1998 (88.2%)** 1192 (82.2%)** 1069 (76.0%)** 952 (92.2%)**
History of diabetes mellitus, n (%) 174 (7.7%)** 120 (8.3%)** 138 (9.8%) 173 (16.8%)**
History of stroke or TIA, n (%) 234 (10.3%) 137 (9.4%)* 170 (12.1%) 133 (12.9%)*
History of MI, n (%) 253 (11.2%)** 232 (16.0%)* 267 (19.0%)** 173 (16.8%)*
History of vascular disease, n (%) 880 (38.8%)** 710 (48.9%)** 853 (60.7%)** 443 (42.9%)
Current smoker, n (%) 339 (15.0%)** 182 (12.5%)** 216 (15.4%)** 136 (13.2%)**
Body mass index (kg/m2) 27.82 (4.43)** 27.31 (4.02)** 27.19 (4.13)** 27.67 (4.37)**
Total cholesterol (mmol/L) 5.78 (0.91)** 5.72 (0.89) 5.67 (0.89) 5.68 (0.91)
Blood pressure
Systolic blood pressure (mmHg) 154.97 (21.24)* 155.52 (23.33) 153.83 (21.71)** 158.77 (23.52)**
Diastolic blood pressure (mmHg) 84.28 (11.41)* 83.69 (0.30) 82.40 (11.47)** 85.53 (12.33)**
Estimated glomerular filtration rate (ml/
min/1.73m2)
56.86 (14.06)** 58.69 (15.23)** 58.00 (13.44)** 59.19 (14.19)*
Data are presented as mean (standard deviation) unless stated otherwise. Abbreviations: n, number; BP, blood pressure; 
TIA, transient ischemic attack; MI, myocardial infarction. **p<0.001 *p<0.05 representing the differences in charac-
teristics between participants taking a specific blood pressure lowering medication class, and participants not taking 
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in participants taking loop diuretics and highest in participants taking RAS-inhibitors. 
Participants taking calcium antagonists had the lowest mean diastolic blood pressure and 
participants taking RAS-inhibitors had the highest mean diastolic blood pressure. 
The association between blood pressure lowering medication and visit-to-visit blood pres-
sure variability is shown in table 2. Participants taking beta-blockers and RAS-inhibitors had 
a higher variability in systolic blood pressure (mean difference in systolic blood pressure 
variability when compared to participants not taking this medication class in mmHg (95% 
CI) 0.75 (0.45; 1.04) and 1.37 (1.04; 1.71) respectively). Results remained significant when 
further adjusting for use of other blood pressure lowering medication, number of blood 
pressure lowering medications, average systolic blood pressure during follow-up and car-
diovascular diseases and risk factors. Participants taking diuretics, calcium antagonists and 
RAS-inhibitors had a higher diastolic blood pressure variability (mean difference in diastolic 
blood pressure variability when compared to participants not taking this medication class 
in mmHg 0.27 (0.04; 0.49), 0.37 (0.12; 0.62) and 0.65 (0.37; 0.93) SD, respectively). Re-
sults remained materially the same when further adjusting for use of other blood pressure 
lowering medication, number of blood pressure lowering medications, average diastolic 
blood pressure during follow-up and cardiovascular diseases and risk factors.
Table 3 shows the association of blood pressure lowering medication with cognitive func-
tion and decline. At baseline, there were no differences in Stroop test, Letter-Digit Coding 
test, and immediate and delayed Picture-Word Learning tests between participants taking 
diuretics, beta-blockers and RAS-inhibitors when compared to participants taking not this 
medication class. Participants taking calcium-antagonists had a higher score in Letter-Digit 
Coding test at baseline (mean difference (95% CI) 0.45 (0.06; 0.88). Participants taking 
beta-blockers had a steeper decline in Stroop test (additional change in seconds per year 
(95% CI) 0.40 (0.09; 0.70) and in Letter-Digit Coding test (additional change in digits coded 
per year (95% CI) -0.08 (-0.15; -0.02). Furthermore, participants taking RAS-inhibitors had 
a worse performance in Stroop test during follow-up (additional change in seconds per 
year (95% CI) 0.50 (0.16; 0.85). No differences in cognitive decline were found between 
participants using diuretics and calcium antagonists when compared to participants not 
using these medication classes.
Furthermore, we investigated whether the association between blood pressure variability 
and cognition was mediated by blood pressure lowering medication (table 4). When we 
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estimates for cognitive function did not essentially change. Furthermore, when we ad-
justed for all blood pressure lowering medication, beta estimates also remained essentially 
the same. 
An additional sensitivity analysis in which we excluded all participants (n=2,766) who 
changed their blood pressure lowering medication during follow-up, revealed materially 
the same results (supplemental tables 1, 2 and 3; available on request). 
Discussion
In this prospective cohort study including 5,606 men and women with a mean age of 
75 years, we showed that blood pressure lowering medication, including diuretics, beta-
blockers, calcium-channel blockers and RAS inhibitors, did not mediate the association 
between high levels of blood pressure variability and cognitive impairment.
The last few years, visit-to-visit blood pressure variability has received increasing attention, 
especially in the association with cardiovascular diseases and cognitive impairment. The 
association between blood pressure lowering medication and visit-to-visit blood pressure 
variability has previously been investigated by Rothwell and colleagues.(4) They hypoth-
esized that class-specific differences of antihypertensive medication in preventing stroke 
might be due to their different effects on visit-to-visit blood pressure variability.(5) In their 
systematic review and meta-analysis, they showed that inter-individual systolic blood pres-
sure variability was reduced the most by calcium-antagonists and non-loop diuretic drugs, 
and increased by ACE-inhibitors, angiotensin-2-receptor blockers and beta-blockers.(12) 
Besides the association with lower systolic blood pressure variability, these findings are in 
line with our results, in which we also showed higher systolic blood pressure variability in 
participants taking beta-blockers and RAS-inhibitors. 
The underlying mechanism by which blood pressure lowering medication is associated 
with blood pressure variability, has not been fully understood. Although most blood pres-
sure lowering medications have an effect on reducing blood pressure variability, there is 
evidence that the most effective are those acting on the arterial baroreflex and calcium 
channel.(20) Furthermore, previous studies showed that calcium antagonists and diuretics 
have arterial effects, including reduction of arterial stiffness and vasoconstriction, by which 
blood pressure variability is also reduced.(21, 22) Cumulative evidence from animal studies 
shows that higher levels of blood pressure variability produce lesions of arterial endothelial 
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cells, activation of the renin-angiotensin system, and inflammation.(20) Subsequently, 
this may lead to impaired cerebral microvasculature and hemodynamics, with comprised 
cerebral flow and eventually, impaired cerebral function. Future studies are needed to 
identify underlying mechanisms of the effects of blood pressure lowering medication on 
blood pressure variability.
Although this study provides evidence for an association between classes of blood pressure 
lowering medication and higher blood pressure variability, we found no proof that blood 
pressure lowering medication mediates the previously demonstrated relation of blood pres-
sure variability with cognitive impairment. A possible explanation for this might be that the 
magnitude of effect of blood pressure lowering medication on blood pressure variability 
was relatively low, and only accounts for a small proportion of all variability. A second 
explanation might be that blood pressure lowering medication itself did not associate with 
cognitive function, which strengthens the finding that blood pressure variability, indepen-
dent of blood pressure lowering medication, is associated with cognitive impairment. 
One important issue that merits further discussion is the principle of confounding by 
indication, in which allocation of treatment may reflect a decision influenced by patient 
characteristics and prognostic factors.(23) Indeed, we found that characteristics of the 
study participants differed across classes of blood pressure lowering medication in the 
population under study, of which the high prevalence of diabetes mellitus in participants 
taking RAS-inhibitors is an example. In addition, besides blood pressure lowering medica-
tion, many other factors influence blood pressure variability, such as incident diseases, in-
flammation pathways and baroreceptor regulation.(3, 24) Although adjusting for possible 
confounders like histories of cardiovascular diseases and risk factors did not essentially 
change our results, our findings could still have been affected by unknown or unmeasured 
factors. Furthermore, another limitation could be that the combination of several drugs of 
one participant may be modifying the associations of blood pressure lowering medication 
with both blood pressure variability and cognitive function. However, when we adjusted 
our analyses for number of blood pressure lowering medications, our results did not 
materially change. Strength of our study is the large sample of participants taking blood 
pressure lowering medication, who all had repeated measures of blood pressure over a 
mean follow-up period of 3.2 years. Furthermore, the prospective nature of this study 
allowed us to study our research question in a clinical setting, rather than a trial context.
In conclusion, we found that use of beta-blockers and RAS-inhibitors was associated with 
higher levels of blood pressure variability. Furthermore, blood pressure lowering medica-
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Cardiac biomarkers in cognitive function

Chapter 5
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Background Elevated levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) are 
associated with cognitive impairment, which might be explained by cardiovascular diseases 
or risk factors. The aim of this study was to investigate the association of NT-proBNP with 
cognitive function and decline in older adults at high risk of cardiovascular disease. 
Methods We studied 5,205 men and women (mean age 75 years) who were included in 
the PROspective Study of Pravastatin in the Elderly at Risk. All participants had pre-existing 
cardiovascular disease or risk factors thereof. Four domains of cognitive function were 
tested at baseline and repeated during a follow-up period of 3.2 years. 
Results Participants with higher NT-proBNP (≥450 ng/L) had worse baseline cognitive 
function including reaction time (mean difference high vs. low group=3.07 seconds, 95% 
confidence interval (CI)=0.83 to 5.32), processing speed (-1.02 digits coded, 95% CI=-1.65 
to -0.39) and immediate memory (-0.13 pictures remembered, 95% CI=-0.29 to 0.04). 
There was no significant difference in delayed memory (-0.14 pictures remembered, 95% 
CI =-0.38 to 0.10) between the NT-proBNP groups. Participants with higher NT-proBNP 
had a steeper cognitive decline, including reaction time (mean annual change high vs. low 
group=0.60 seconds, 95% CI=0.14 to 1.07), processing speed (-0.15 digits coded, 95% 
CI=-0.25 to -0.05), immediate memory (-0.05 pictures remembered, 95% CI=-0.09 to 
0.00), and delayed memory (-0.05 pictures remembered, 95% CI=-0.11 to 0.01). Associa-
tions were independent of cardiovascular diseases and risks. 
Conclusion Higher NT-proBNP levels associate with worse cognitive function and steeper 
cognitive decline in older adults, independent of cardiovascular diseases and risks. Further 
studies to unravel the underlying mechanisms are warranted.




Higher levels of N-terminal pro-brain natriuretic peptide (NT-proBNP), a neurohormone 
produced by cardiomyocytes in response to ventricular stretch, have been associated with 
cognitive impairment.(1-4) Evidence comes from several cross-sectional studies, which 
show that among community-dwelling older adults, higher NT-proBNP levels were associ-
ated with worse cognitive function, in particular memory.(1-4) There are limited numbers 
of longitudinal studies with relatively small sample sizes, which demonstrate that higher 
NT-BNP levels are also associated with steeper declines in Mini-Mental State Examination 
(MMSE) scores and higher incidence of dementia.(5, 6) A potential mechanism behind 
the relationship between higher NT-proBNP levels and cognitive function is clinical heart 
failure, resulting in left ventricular dysfunction with subsequent reduced cardiac output. It 
is hypothesized that reduced cardiac output causes inadequate cerebral perfusion, lead-
ing to a higher risk of cognitive impairment.(7-9) Improvements in cognitive function in 
patients following cardiac transplantation suggests that impaired cardiac function might 
be a reversible risk factor for cognitive impairment.(10, 11)
Recent evidence demonstrates that higher NT-proBNP levels in older adults are strongly as-
sociated with cardiovascular diseases and risk factors and predict an increased risk of atrial 
fibrillation, stroke, transient ischemic attack, myocardial infarction and mortality, even 
in the absence of clinical heart failure.(12-15) In addition, higher NT-proBNP levels have 
been related to left ventricular hypertrophy and systolic and diastolic dysfunction in adults 
without clinical heart failure.(16, 17) The relationship of cardiovascular diseases and risk 
factors with cognitive impairment is well-established.(18, 19) Hence, cognitive impairment 
might already be present in asymptomatic older adults at early stages of reduced cardiac 
function. 
We hypothesized that elevated levels of NT-proBNP are associated with a steeper cognitive 
decline in older adults, which might be explained by cardiovascular diseases or risk factors. 
Therefore, we studied the cross-sectional and longitudinal association of NT-proBNP with 
cognitive function in a cohort of older men and women from the PROspective Study of 
Pravastatin in the Elderly at Risk (PROSPER), in which all participants had either preexisting 





Data were obtained from the PROspective Study of Pravastatin in the Elderly at Risk (PROS-
PER), a randomized, double-blind, placebo-controlled trial designed to investigate the 
effect of pravastatin in prevention of vascular events in older individuals with pre-existing 
cardiovascular disease or risk factors thereof. This trial was conducted between 1997 and 
2002 and included 5,804 men and women aged 70-82 years old who were enrolled from 
three collaborating centers in Ireland, Scotland and the Netherlands. Approximately 50% 
of the participants had cardiovascular disease including stable angina, intermittent claudi-
cation, stroke, transient ischemic attack, myocardial infarction and/or vascular surgery. The 
rest of participants had one or more cardiovascular risk factor, defined as hypertension, 
smoking or diabetes mellitus. Primary outcome of the trial was the combined endpoint of 
definite or suspect death from coronary heart disease, non-fatal myocardial infarction and 
fatal or non-fatal stroke during a mean follow-up period of 3.2 years. The institutional eth-
ics committees of the three collaborating centers approved the study and all participants 
gave written informed consent.(20, 21)
Study participants
All participants had pre-existing cardiovascular disease or risk factors thereof (defined as a 
history of hypertension, diabetes mellitus or current smoking). Participants with congestive 
heart failure, defined as New York Heart Association functional class III or IV, were excluded 
from the original PROSPER trial.(20) No information on NYHA class I or II was available. For 
the present study, we additionally excluded participants with heart failure hospitalization 
during follow-up (n=205). 
NT-proBNP measurements
Blood samples were taken at 6 months after follow-up in EDTA tubes.(20) NT-proBNP was 
determined using electrochemiluminescence immunoassay on a Roche Modulator E170. 
A number of 394 participants had missing NT-proBNP measurements. In line with existing 
literature on cutoff values in this age group, we defined three groups of NT-proBNP: low 
(<100 ng/L), middle (100-450 ng/L) and high NT-proBNP (≥450 ng/L).(1) Furthermore, these 
cutoff values were chosen from a pragmatic approach, to allow direct interpretation for 
clinical practice.




The MMSE was used to evaluate global cognitive function; participants with a baseline score 
below 24 points were not included in PROSPER. Cognitive function was tested at baseline 
and at 9, 18, 30 months and at the end of the study. The time-point of the measurement 
at the end of the study varied between 36 and 48 months; therefore, we performed the 
analysis with their individually varying time point, but report the results for the mean of 
these time points (at 42 months). Since PROSPER was conducted in three countries with 
in total two languages (Dutch and English), care was taken to select tests that are not sen-
sitive to language. Furthermore, all analyses were adjusted for country.(22) Four different 
neuropsychological tests were used to assess executive function, attention, and immediate 
and delayed memory. The Stroop-Colour-Word-Test was used to test selective attention and 
reaction time. Participants were asked to read a color name which was displayed in a color 
different from the color it actually names. Outcome parameter was the total number of 
seconds to complete the test; a higher score indicates worse performance. General cognitive 
speed was tested by the Letter-Digit Coding Test. Participants had to match certain digits 
with letters according to a provided key. Outcome variable was the total number of correct 
entries in 60 seconds, therefore higher scores represented better performance. The Picture-
Word Learning Test was used to assess immediate and delayed memory. Fifteen pictures were 
presented, and participants were asked to recall as many pictures as possible in three trials. 
After 20 minutes they were asked to repeat the pictures they remembered to measure their 
delayed recall. Outcome parameter was the accumulated number of correct recalled pictures, 
immediate and after 20 minutes. Higher scores thus indicate better performance. A detailed 
description of the cognitive tests has been published previously.(22) Since treatment with 
pravastatin did not influence cognitive function during follow-up, we included participants 
from both pravastatin and placebo groups.(23)
Statistical analysis
Baseline characteristics of the study participants are reported as number (percentage) 
for categorical variables and mean (standard deviation) for continuous variables for each 
group of NT-proBNP. Differences in categorical variables were tested by Chi-squared tests. 
Differences in continuous variables were tested with linear regression models. Since NT-
proBNP levels were not normally distributed, we used log-transformed NT-proBNP levels to 
calculate p-values for continuous variables. To investigate the cross-sectional association 
of NT-proBNP with cognitive function, we used linear regression models. Log-transformed 
NT-proBNP levels were included as independent variable; outcome variable was the mean 
baseline score on each of the four cognitive function tests. Linear mixed models were 
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used to examine the association between NT-proBNP and cognitive decline over time. The 
models included log-transformed NT-proBNP levels, time (in years) and the interaction term 
between time and log-transformed NT-proBNP levels. 
We performed our analyses in three steps. In the first step, crude analyses were performed, 
in which we only adjusted for cognitive test version where appropriate. In the second step, 
we added the variables age, sex, education (age left school), country and Apo E genotype 
to the model to investigate the potential influence of these factors on the associations 
(minimally adjusted model). Furthermore, in a fully adjusted model we also added the fol-
lowing potential confounders: cardiovascular diseases and risk factors at baseline (history 
of cerebrovascular and cardiovascular disease, hypertension, diabetes mellitus, smoking 
status, HDL and LDL cholesterol levels, triglycerides, systolic and diastolic blood pressure, 
body mass index), statin treatment and estimated glomerular filtration rate (eGFR). Since 
the associations did not essentially change in various models, we present the results of the 
minimally and fully adjusted models only. 
To further explore the influence of cardiovascular diseases and risk factors, additional analy-
ses were performed in which we stratified for history of cardiovascular diseases and risk 
factors. To test whether the difference between participants with or without a history of 
cardiovascular disease or risk factor was significant, we calculated a p-value for interaction 
by using linear regression models. Furthermore, we performed additional sensitivity analy-
ses in which we excluded 1) participants taking pravastatin treatment during follow-up; 
2) participants with incident stroke and/or transient ischemic attack; 3) participants with 
incident myocardial infarction; 4) participants with incident atrial fibrillation; 5) participants 
with vascular events, including coronary heart disease death, nonfatal myocardial infarc-
tion, nonfatal and fatal stroke and/or TIA; 6) participants with NT-proBNP of ≥450 ng/L; and 
7) participants taking loop diuretics, beta blockers or ace-inhibitors at baseline. 
Results
Participants with heart failure hospitalization during follow-up were excluded (n=205). 
A number of 394 participants had missing NT-proBNP measurements, resulting in a total 
number of 5205 participants for the present study. 
Table 1 shows characteristics of participants grouped by NT-proBNP levels. Participants 
with higher NT-proBNP levels were older and had a higher prevalence of hypertension, 
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myocardial infarction, vascular disease and smoking (all p-values <0.001). Body mass index 
was lower in participants with higher NT-proBNP levels (p-value <0.001). Systolic blood 
pressure, pulse pressure and mean arterial blood pressure were higher among participants 
with higher NT-proBNP levels (p-values <0.001, p<0.001 and p=0.001 respectively). Fur-
thermore, participants with higher NT-proBNP levels had a steeper decline in systolic and 
diastolic blood pressure during follow-up (p-values <0.001 and 0.001 respectively). Use 
of loop diuretics, beta blockers and ace-inhibitors was higher in participants with higher 
NT-proBNP levels (p-values <0.001, p<0.001 and p=0.031 respectively). Participants with 
higher NT-proBNP levels had lower eGFR (p <0.001).













Age (years), mean (SD) 74.42 (3.04) 75.53 (3.37) 76.59 (3.40) <0.001
Female, n (%) 850 (46.8) 1490 (55.2) 360 (52.2) <0.001
Education (age left school), mean (SD) 15.17 (2.06) 15.15 (2.06) 15.10 (2.08) 0.083
Vascular risk factors
History of hypertension, n (%) 1056 (58.1) 1736 (64.3) 444 (64.4) <0.001
History of diabetes mellitus, n (%) 245 (13.5) 245 (9.1) 57 (8.3) <0.001
History of stroke or TIA, n (%) 189 (10.4) 301 (11.2) 85 (12.3) 0.371
History of myocardial infarction, n (%) 120 (6.6) 369 (13.7) 177 (25.7) <0.001
History of vascular disease, n (%) 630 (34.7) 1246 (46.2) 393 (57.0) <0.001
Current smoker, n (%) 536 (29.5) 667 (24.7) 175 (25.4) 0.001
Body mass index (kg/m2), mean (SD) 27.22 (4.02) 26.69 (4.21) 26.17 (4.20) <0.001
Total cholesterol (mmol/L), mean (SD) 5.68 (0.90) 5.68 (0.91) 5.70 (0.93) 0.461
Systolic blood pressure (mmHg), mean (SD)# 152.60 (20.25) 155.11 (21.75) 158.75 (23.50) <0.001
Diastolic blood pressure (mmHg), mean (SD)# 84.02 (10.95) 83.73 (11.33) 83.38 (12.01) 0.158
Pulse pressure (mmHg), mean (SD) 68.58 (0.42) 71.38 (0.35) 75.37 (0.68) <0.001
Mean Arterial Pressure (mmHg), mean (SD) 106.88 (0.30) 107.53 (0.25) 108.51 (0.49) 0.001
Systolic blood pressure trend (mmHg), mean (SD) -0.97 (7.94) -1.49 (9.60) -2.88 (12.44) <0.001
Diastolic blood pressure trend (mmHg), mean (SD) -1.25 (4.70) -1.52 (5.25) -1.93 (7.03) 0.001
Blood pressure lowering medication, n (%)
Diuretics 650 (35.8) 1067 (39.5) 269 (39.0) <0.001
Loop 153 (8.4) 327 (12.1) 107 (15.5) <0.001
Other 497 (27.3) 740 (27.4) 162 (23.5)
Calcium channel blockers 459 (25.2) 692 (25.6) 151 (21.9) 0.125
Beta blockers 241 (13.3) 831 (30.8) 273 (39.6) <0.001
Ace-inhibitors 279 (15.3) 421 (15.6) 134 (19.4) 0.031
eGFR, mean (SD) 62.77 (13.79) 59.64 (14.48) 55.54 (14.99) <0.001
*Probability values were calculated using log-transformed NT-proBNP levels for continuous variables and chi-squared 
tests for categorical variables. #Defined as the regression coefficient per year. Abbreviations: ACE=angiotensin-con-
verting enzyme; eGFR=estimated glomerular filtration rate; NT-proBNP=N-terminal pro-brain natriuretic peptide; 
SD=standard deviation ; TIA=transient ischemic attack. 
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Table 2 shows the association of NT-proBNP levels with cognitive function at baseline. 
In the minimally adjusted model, participants with higher NT-proBNP levels had worse 
performance on the Stroop test (p=0.003) and the Letter-Digit Coding test (p<0.001). The 
same trend was observed for immediate and delayed Picture-Word Learning tests, show-
ing that participants with higher NT-proBNP levels had worse performance, albeit these 
associations were not significant (p-value=0.060 and p=0.066 respectively). When further 
adjusting for prevalent cardiovascular diseases or risk factors at baseline, the estimates of 
the difference in cognitive function between the groups remained essentially the same. 
The association of NT-proBNP levels with the Stroop test and Letter-Digit Coding test in 
the fully adjusted model remained significant (p-value=0.003 and p<0.001 respectively), 
whereas for immediate and delayed Picture-Word Learning tests the associations were 
not significant (p-value=0.091 and p=0.062 respectively). Data on the association of NT-
proBNP with cognitive function from crude models did not materially differ from minimally 
and fully adjusted models (data not shown). 
Table 3 and Figure 1 show the association of NT-proBNP levels with changes in cognitive 
function during a mean follow-up period of 3.2 years. Participants with higher NT-proBNP 














Minimally adjusted model 64.37 (1.46) 64.15 (1.42) 67.40 (1.63) 0.003
Fully adjusted model 66.23 (1.56) 66.09 (1.53) 69.30 (1.72) 0.003
LDCT, digits coded
Minimally adjusted model 23.94 (0.41) 23.54 (0.40) 23.02 (0.46) <0.001
Fully adjusted model 23.33 (0.44) 22.88 (0.43) 22.31 (0.48) <0.001
PLTi, pictures remembered
Minimally adjusted model 9.58 (0.11) 9.52 (0.11) 9.44 (0.12) 0.060
Fully adjusted model 9.49 (0.12) 9.44 (0.12) 9.37 (0.13) 0.091
PLTd, pictures remembered
Minimally adjusted model 10.43 (0.16) 10.40 (0.15) 10.29 (0.17) 0.066
Fully adjusted model 10.22 (0.17) 10.19 (0.16) 10.08 (0.18) 0.062
Data represent mean (standard error) score of each cognitive function test. Minimally adjusted model: adjusted for age, 
sex, country, education (age on leaving school), ApoE genotype, treatment group, test version for LDCT and PLT. Fully 
adjusted model: minimally adjusted model + adjustments for history of cerebrovascular and cardiovascular disease, his-
tory of hypertension, history of diabetes mellitus, current smoking, baseline systolic and diastolic blood pressure, HDL 
and LDL cholesterol, triglycerides, body mass index, and estimated gloermular filtration rate. *Probability values were 
calculated using the continuous value of log-transformed NT-proBNP levels. Abbreviations: LDCT=Letter-Digit Coding 
Test; NT-proBNP=N-terminal pro-brain natriuretic peptide; test; PLTd=Picture-Word Learning test, delayed; PLTi=Picture-
Word Learning test, immediate. 
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levels had a steeper cognitive decline on the Stroop test, Letter-Digit Coding test and 
immediate and delayed Picture-Word Learning tests (all p-values≤0.001). Again, further 
adjustments for prevalent cardiovascular diseases or risk factors at baseline did not ap-
preciably alter the observed associations (all p-values≤0.001). The association of NT-proBNP 
levels with cognitive decline from crude models did not materially differ from adjusted 
models (data not shown). 
To further explore the influence of cardiovascular diseases and risk factors, we performed 
additional analyses in which we stratified for history of various cardiovascular diseases 
and risk factors, and tested for interaction. Figure 2 shows the association of NT-proBNP 
levels with cognitive decline, stratified by history of cardiovascular diseases and risk factors. 
There was no significant difference in change in cognitive function during follow-up be-
tween participants with and without cardiovascular diseases or risk factors, except on the 
Letter-Digit Coding test for participants with a history of stroke and/or transient ischemic 
attack (TIA) and myocardial infarction. Participants with previous stroke and/or TIA had a 
less steep decline on Letter-Digit Coding test (p for interaction=0.003), while participants 
with previous myocardial infarction had a steeper decline on Letter-Digit Coding test (p 
Table 3. Association of NT-proBNP with cognitive decline during follow-up 
Cognitive tests  












Minimally adjusted model 0.46 (0.11) 0.71 (0.09) 1.04 (0.26) 0.001
Fully adjusted model 0.47 (0.11) 0.72 (0.09) 1.04 (0.26) 0.001
LDCT, digits coded
Minimally adjusted model -0.32 (0.02) -0.36 (0.02) -0.46 (0.04) 0.001
Fully adjusted model -0.32 (0.02) -0.35 (0.02) -0.47 (0.04) <0.001
PLTi, pictures remembered
Minimally adjusted model -0.00 (0.01) -0.03 (0.01) -0.05 (0.02) <0.001
Fully adjusted model 0.00 (0.01) -0.02 (0.01) -0.04 (0.02) <0.001
PLTd, pictures remembered
Minimally adjusted model -0.05 (0.01) -0.06 (0.01) -0.10 (0.03) 0.001
Fully adjusted model -0.03 (0.01) -0.05 (0.01) -0.10 (0.03) 0.001
Data represent mean annual change (standard error) in each cognitive function test. Minimally adjusted model: ad-
justed for age, sex, country, education (age on leaving school), ApoE genotype, treatment group, test version for LDCT 
and PLT.Fully adjusted model: minimally adjusted model + adjustments for history of cerebrovascular and cardiovascular 
disease, history of hypertension, history of diabetes mellitus, current smoking, baseline systolic and diastolic blood 
pressure, HDL and LDL cholesterol, triglycerides, body mass index, and estimated glomerular filtration rate. *Prob-
ability values were calculated using the interaction term of time and log-transformed NT-proBNP levels.Abbreviations: 
LDCT=Letter-Digit Coding test; NT-proBNP=N-terminal pro-brain natriuretic peptide; PLTd, Picture-Word Learning test, 
delayed; PLTi=Picture-Word Learning test, immediate
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for interaction=0.008). However, no such differences were observed for participants with 
previous stroke and/or TIA or myocardial infarction on any of the other cognitive tests. 
Furthermore, we performed additional sensitivity analyses to investigate whether the as-
sociation between NT-proBNP levels and cognitive function and decline could be affected 
by 1) participants taking pravastatin treatment during follow-up (n=2,588); 2) participants 
with incident stroke and/or TIA during follow-up (n=355); 3) participants with incident 
myocardial infarction during follow-up (n=339); 4) participants with incident atrial fibril-
lation during follow-up (n=421); 5) participants with vascular events, including coronary 
heart disease death, nonfatal myocardial infarction, nonfatal and fatal stroke and/or TIA 
during follow-up (n=648); 6) participants with NT-proBNP levels of ≥ 450 ng/L; and 7) par-
ticipants taking loop diuretics (n=588), beta blockers (n=1,345) or ace-inhibitors (n=834) 
at baseline. Exclusion of these participants did not essentially change our results (data 
available on request).
Figure 1. Association of NT-proBNP with cognitive decline during follow-up
Data represent mean score (95% confidence interval) of each cognitive test during follow-up, in each group of NT-
proBNP. Because the time-point of the measurement at the end of the study varied between 36 and 48 months, the 
mean of these time points (42 months) is reported. Probability values were calculated using the interaction term of 
time and log-transformed NT-proBNP levels. Adjustments were made for age, sex, country, education, ApoE genotype, 
treatment group and test version where appropriate.




In this prospective cohort study including over 5,000 men and women with mean age of 
75 years, we showed that participants with higher NT-proBNP levels had worse cognitive 
Figure 2. Association of NT-proBNP with cognitive decline during follow-up, stratified by cardiovascular dis-
eases and risk factors
Data represent mean annual change (95% confidence interval) per 1 ng/L increase in log-transformed NT-proBNP for 
each cognitive test, stratified by cardiovascular diseases. Probability values were calculated using the interaction term of 
cardiovascular disease and log-transformed NT-proBNP level and represent the statistical difference in annual change in 
cognitive function between participants with and without cardiovascular disease or risk factors. Adjusted for age, sex, 




function and steeper cognitive decline during a mean period of 3.2 years. These associa-
tions were independent of cardiovascular diseases and risk factors. 
Our findings are in line with previous cross-sectional studies, showing that higher NT-
proBNP levels were associated with worse memory and with lower global and executive 
cognitive function.(1-4) Only few longitudinal studies with limited number of participants 
investigated the association between NT-proBNP and cognition during follow-up. They 
showed that higher NT-proBNP levels are associated with a steeper decline in Mini-Mental 
State Examination (MMSE) scores and a higher incidence of dementia during a mean 
follow-up period of 5 years.(5, 6) To our knowledge, this is the first study reporting on the 
association of NT-proBNP and cognitive function and decline, using an extended standard-
ized test battery over a mean follow-up period of 3.2 years, in a large cohort of older adults 
with pre-existing cardiovascular disease or risk factors thereof.
Brain natriuretic peptide (BNP) and the biologically inactive N-terminal pro-brain natriuretic 
peptide are secreted by the ventricles of the heart in response to excessive stretching 
of cardiomyocytes.(24) BNP has favorable physiological properties, including increased 
natriuresis and diuresis, relaxation of vascular smooth muscle cells and inhibition of the 
renin-angiotensin-aldosterone-axis, eventually causing a reduction in blood pressure and 
ventricular preload.(24) Our results showed that higher NT-proBNP levels were associated 
with higher systolic blood pressure. Initially, higher systolic blood pressure might increase 
the ventricular stress of cardiomyocytes and therefore causes an increased release of 
NT-proBNP. In case of chronic ventricular stress, this might further proceed to reduced 
cardiac function and heart failure. Subsequently, cardiac output will be reduced and blood 
pressure will be lower.(9)
Different explanations can be proposed for the observed association of NT-proBNP with 
cognitive decline. First, NT-proBNP and cognitive decline are highly likely to reflect underly-
ing cardiovascular damage and therefore stem from common causes. Previous studies have 
shown that NT-proBNP levels have a prognostic value for the occurrence of cardiovascular 
events, such as myocardial infarction, atrial fibrillation, coronary heart disease, unstable 
angina, stroke and transient ischemic attack.(12, 15, 25, 26) This has also been dem-
onstrated in subjects with elevated NT-proBNP levels, but without clinical heart failure.
(27) Furthermore, NT-proBNP levels provide predictive information for use of risk stratifica-
tion in nonfatal cardiac events, stroke and mortality in range of populations including 
diabetes.(26, 28-30) These cardiovascular and metabolic diseases are closely linked to 
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cognitive dysfunction and dementia.(18, 19) This is in line with the finding that high NT-
proBNP levels are associated with an increased prevalence of cardiovascular diseases and 
risk factors in the population under study. However, when adjusting and stratifying our 
analyses for cardiovascular diseases and risk factors, our results did not appreciably alter. 
Furthermore, excluding participants with incident myocardial infarction, stroke and/or TIA 
showed the same results. Nevertheless, we cannot rule out the possibility that unmeasured 
cardiovascular risk factors resulted in both increased NT-proBNP and cognitive decline. 
Second, impaired cardiac function may activate the renin-angiotensin system which in turn 
has been associated with cognitive decline.(31) In line with this evidence, observational 
studies have suggested that subjects receiving angiotensin receptor blockers may have a 
lower risk of developing dementia.(32, 33) Since only a small number of participants used 
angiotensin receptor blockers in the population under study (n<100), we could not further 
investigate this issue. Third, since natriuretic peptides have first been identified in porcine 
brain extract, one could hypothesize that NT-proBNP could have a direct effect in the brain. 
Although there is evidence that natriuretic peptides have receptors on endothelial cells, it 
is, to our knowledge, unknown whether NT-proBNP alters cerebral autoregulation.(7, 34) 
A fourth explanation might be that high NT-proBNP levels in subjects without advanced 
stages of heart failure indicate a suboptimal left ventricular functioning with subsequent 
decreased cardiac output and cerebral hypoperfusion.(9, 16) Cerebral hypoperfusion, 
which impairs the delivery of oxygen and nutrients to the brain, has been associated with 
cognitive dysfunction and dementia.(7-9) Although this explanation seems plausible, there 
is a need for interventional studies investigating the influence of improvement in cardiac 
function with its subsequent influence on cerebral perfusion, and eventually the preven-
tion of cognitive decline in old age.
The present study found that participants with previous stroke and/or TIA had a less steep 
decline on Letter-Digit Coding test, which is unexpected and not in line with previous 
literature. Nevertheless, no differences were observed for participants with previous stroke 
and/or TIA on the Stroop test, immediate Picture-Word Learning test and delayed Picture 
Word Learning test. Furthermore, as there was no significant association between NT-
proBNP levels and history of stroke and/or TIA, we could not explain this association from 
a biologically perspective. Therefore, we believe that the most likely explanation for this 
finding is chance.
Major strengths of this study include the large sample size of over 5000 older participants 
and the repeated use of an extended standardized cognitive test battery to assess cognitive 
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function over a mean follow-up period of 3.2 years. Furthermore, in contrast to previous 
studies, participants with NYHA functional class III/IV were excluded, which gave us the 
opportunity to investigate NT-proBNP in relation with cognitive function and decline in 
participants without advanced stages of clinical heart failure. However, a limitation of the 
study is that there was no information on the incidence of dementia during follow-up, nor 
was there information on cardiac functioning or NYHA class I or II. We might therefore 
have included participants with (beginning stages of) clinical heart failure, without ever be-
ing diagnosed with this condition. However, excluding participants with NT-proBNP levels 
of ≥ 450 ng/L showed essentially the same results. As high NT-proBNP levels have been 
recognized as predictor of heart failure, this finding further suggests an association be-
tween NT-proBNP and cognitive decline.(35) Furthermore, our study population consisted 
of older participants at risk of cardiovascular diseases with relatively preserved cognitive 
function (MMSE ≥ 24 points), which might limit extrapolation of our findings to a general 
population of older subjects. 
In conclusion, higher NT-proBNP levels associate with worse cognitive function and steeper 
cognitive decline in older adults, independent of cardiovascular diseases and risks. Further 
studies to unravel the underlying mechanisms are warranted.
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Background Cardiac troponin T (cTnT), measured with a high-sensitivity (hs) assay, is asso-
ciated with cognitive decline, but the underlying mechanism is unknown. We investigated 
the association of hs-cTnT with cognitive function and decline, and studied whether this 
association was independent of cardiovascular diseases or risk factors, and N-terminal pro-
brain natriuretic peptide (NT-proBNP).
Methods We studied 5,407 participants (mean age 75.31 years) from the PROspective 
Study of Pravastatin in the Elderly at Risk, who all had cardiovascular diseases or risk fac-
tors thereof. Participants with pre-existent advanced clinical heart failure were excluded. 
Hs-cTnT and NT-proBNP obtained after 6 months of follow-up were related with cognitive 
function, which was tested repeatedly during a mean follow-up of 3.2 years. 
 
Results Participants with higher hs-cTnT performed worse at baseline on Stroop test (mean 
baseline score (standard error (SE)) lowest vs. highest third 65.91 (1.16) vs. 69.40 (1.10) 
seconds, p<0.001), Letter-Digit Coding test (23.35 (0.32) vs. 22.40 (0.31) digits coded, 
p<0.001), immediate Picture-Word Learning test (9.45 (0.09) vs. 9.31 (0.08) pictures 
remembered, p=0.002) and delayed Picture-Word Learning test (10.33 (0.12) vs. 10.10 
(0.12) pictures remembered, p=0.013). Furthermore, participants with higher hs-cTnT had 
steeper decline on Stroop test (mean annual change (SE) lowest vs. highest third 0.34 
(0.12) vs. 1.06 (0.12) seconds, p=0.013), Letter-Digit Coding test (-0.29 (0.03) vs. -0.46 
(0.03) digits coded, p<0.001), immediate Picture-Word Learning test (0.01 (0.01) vs. -0.06 
(0.01) pictures remembered, p<0.001) and delayed Picture-Word Learning test (-0.03 
(0.01) vs. -0.12 (0.02) pictures remembered, p=0.001). Associations were independent 
of cardiovascular diseases risk factors or apoE genotype. Further adjusting for NT-proBNP 
levels revealed the same results.
Conclusion Higher levels of hs-cTnT associate with worse cognitive function and steeper 
cognitive decline in older adults independent of cardiovascular diseases, risk factors and 
NT-proBNP.




Cardiac troponin T (cTnT) is a protein that is released in response to cardiomyocyte necro-
sis, and is routinely used in the diagnosis of acute myocardial infarction.(1) In patients with 
cardiovascular disease, higher levels of cTnT, measured with a high-sensitivity (hs) assay, 
are associated with higher risk of incident coronary heart disease, heart failure and stroke.
(1, 2) Moreover, in patients free from cardiovascular disease, raised levels of hs-cTnT have 
also been associated with higher risk of all-cause mortality and myocardial infarction.(3) 
Cardiovascular diseases are important risk factors for cognitive impairment and dementia.
(4) Recent evidence shows that in subjects without cardiovascular disease, higher levels of 
hs-cTnT are associated with silent brain infarcts and white matter lesion progression.(5) 
Hs-cTnT might therefore be a sensitive systemic marker for structural brain damage, which 
is associated with decreased cognitive function and dementia.(6) Hs-cTnT has recently also 
been associated with cognitive function, but the underlying mechanism is unknown.(7) 
Besides the fact that cardiac disease and cognitive dysfunction share common risk factors 
there may be an alternative explanation. Myocardial ischemia or infarction, as detected by 
increased hs-cTnT, may lead to clinical heart failure or decreased cardiac function, which in 
turn leads to cognitive decline.(8) Given the predicted increase in prevalence of cognitive 
dysfunction in the coming decades, unravelling early predictors of cognitive decline is of 
importance.(9) 
The aims of this study were to investigate 1) whether subjects with higher levels of hs-cTnT 
are at increased risk of worse cognitive function and steeper cognitive decline; 2) whether 
this was independent of cardiovascular diseases or its risk factors, and 3) whether this was 
independent of N-terminal pro-brain natriuretic peptide (NT-proBNP), a marker used in 
the diagnosis of clinical heart failure.(10-12) We used data from the PROspective Study of 
Pravastatin in the Elderly at Risk (PROSPER), which included 5804 older men and women 
who all had a cardiovascular disease or cardiovascular risk factors thereof. 
Methods
Study design and participants
Data were obtained from the PROspective Study of Pravastatin in the Elderly at Risk (PROS-
PER), a randomized, double-blind, placebo-controlled trial designed to investigate the 
effect of pravastatin in prevention of vascular events in older individuals with pre-existing 
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cardiovascular disease or risk factors thereof.(13) Briefly, main inclusion criteria were that 
participants had either pre-existing vascular disease (coronary, cerebral or peripheral) or 
an elevated level of developing vascular disease because of smoking, diabetes mellitus or 
hypertension. Furthermore, their total cholesterol level was required to be between 4.0-9.0 
mmol/L and their triglyceride concentration <6.0 mmol/L. Participants with congestive heart 
failure, defined as New York Heart Association functional class III or IV, were not included 
in the PROSPER study, nor were participants who were previously diagnosed with atrial 
fibrillation.(13) Furthermore, poor cognitive function at baseline, defined as a Mini-Mental 
Score Examination below 24 points, was an exclusion criteria. Participants with congestive 
heart failure, defined as New York Heart Association functional class III or IV, were not 
included in the PROSPER study, nor were participants who were previously diagnosed with 
atrial fibrillation.(13) This trial included 5,804 men and women aged 70-82 years old who 
were enrolled from three collaborating centers in Ireland, Scotland and the Netherlands. 
Approximately 50% of the participants had cardiovascular disease including stable angina, 
intermittent claudication, stroke, transient ischemic attack, myocardial infarction and/or 
vascular surgery. The rest of participants had one or more cardiovascular risk factor, defined 
as hypertension, smoking or diabetes mellitus. Participants with congestive heart failure, 
defined as New York Heart Association functional class III or IV, were not included in the 
PROSPER study.(13) The primary outcome of the trial was the combined endpoint of defi-
nite or suspect death from coronary heart disease, non-fatal myocardial infarction and fatal 
or non-fatal stroke during a mean follow-up period of 3.2 years.(14) The institutional ethics 
committees of the three collaborating centers approved the study and all participants gave 
written informed consent.
cTnT and NT-proBNP measurements 
cTnT and NT-proBNP were measured in blood samples obtained after 6 months of follow-
up in EDTA tubes. Both proteins were measured using an electrochemiluminiscence 
immunoassay on a Roche Modular Analytics E170. The Roche cTnT measurement was 
performed with a high-sensitivity assay, which has a limit of detection of 0.003 ug/L and a 
99th percentile cutoff of 0.014 ug/L. Furthermore, the Elecsys Troponin T hs assay used had 
a CV of 10.38% at a cTNT concentration of 0.010 ug/L, thus the assay is able to differenti-
ate reasonably well at lower concentrations. For those patients who had a level below the 
detection limit, we have assumed these values to be distributed anywhere between zero 
and 0.003, of which the average is 0.0015. Hs-cTnT levels below detection level were 
therefore set to 0.0015 ug/L in the statistical analyses. To further investigate whether the 
association of cTnT with cognitive function and decline was independent of clinical heart 
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failure, we studied participants with low and high NT-proBNP levels more in detail. To be 
sure that participants had no clinical heart failure, we chose a conservative cut-off of 200 
ng/L for NT-proBNP. Furthermore, we stratified our analyses by a less conservative cut-off of 
low (<400 ng/L) and high (≥400 ng/L) NT-proBNP, based on relevant guidelines.(15)
Cognitive function
The MMSE was used to evaluate global cognitive function; participants with a baseline 
score below 24 points were not included in PROSPER.(13) Cognitive function was tested 
at baseline and at 9, 18, 30 months and at the end of the study. The time-point of the 
measurement at the end of the study varied between 36 and 48 months; therefore, we 
performed the analysis with their individually varying time point, but report the results 
for the mean of these time points (at 42 months). Four different neuropsychological tests 
were used to assess executive function, attention, and immediate and delayed memory. 
The Stroop-Colour-Word-Test was used to test selective attention and reaction time. Par-
ticipants were asked to read a color name which was displayed in a color different from the 
color it actually names. Outcome parameter was the total number of seconds to complete 
the test; a higher score indicates worse performance. Processing speed was tested by the 
Letter-Digit Coding Test. Participants had to match certain digits with letters according to 
a provided key. Outcome variable was the total number of correct entries in 60 seconds, 
therefore higher scores represented better performance. The Picture-Word Learning Test 
was used to assess immediate and delayed memory. Fifteen pictures were presented, and 
participants were asked to recall as many pictures as possible in three trials. After 20 
minutes they were asked to repeat the pictures they remembered to measure their delayed 
recall. Outcome parameter was the accumulated number of correct recalled pictures, im-
mediate and after 20 minutes. Higher scores thus indicate better performance. A detailed 
description of the cognitive tests has been published previously.(16) Since treatment with 
pravastatin did not influence cognitive function during follow-up, we included participants 
from both pravastatin and placebo groups.(17)
Statistical analyses
We present our results in thirds of cTnT. Baseline characteristics of the study participants are 
presented as mean (standard deviation) for continuous variables and number (percentage) 
for categorical variables for each third of cTnT. Differences in continuous variables were 
tested with linear regression models; differences in categorical variables were tested by 
Chi-squared tests. Because of the skewed distribution of cTnT levels and log-transformed 
cTnT levels, all analyses were performed using the square root of cTnT, which was normally 
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distributed (supplemental figure 2). To investigate the cross-sectional association of cTnT 
with cognitive function, we used linear regression models. The square root levels of cTnT 
were included as independent variable; outcome variable was the mean baseline score on 
each of the four cognitive function tests. Linear mixed models were used to examine the 
association between cTnT and cognitive decline over time. The models included the square 
root of cTnT level, time (in years) and the interaction term between time and the square 
root of cTnT level. 
We performed our analyses according to two different adjustment models. In the first 
model, we only adjusted for the variables age, sex, country, education, treatment with 
pravastatin or placebo and cognitive test version where appropriate (minimally adjusted 
model). In the second model, we further adjusted for ApoE genotype, history of cerebro-
vascular and cardiovascular disease, history of hypertension, history of diabetes mellitus, 
current smoking, baseline systolic and diastolic blood pressure, high density lipoprotein 
(HDL) and low density lipoprotein (LDL) cholesterol levels, triglycerides, body mass index 
and estimated glomerular filtration rate (eGFR), to investigate the potential influence of 
these factors on the associations. Since the observed associations did not materially dif-
fer, we chose to present the results from comprehensive adjusted models. Results from 
minimally adjusted models are included as supplemental material. Concerning the longi-
tudinal analyses, we further studied the effects of potential confounders on the slope of 
the association by additionally including the interaction terms between time, square root 
of troponin level and potential confounder in the linear mixed models. These results did 
not materially affect the slope of the analyses and we therefore present the results of the 
simple models. Finally, to explore the influence of cardiovascular diseases and risk factors 
in more details, we performed additional analyses in which we stratified for history of 
cardiovascular diseases and risk factors. 
To further investigate whether the association of cTnT with cognitive function and decline 
was independent of clinical heart failure, we stratified our analyses by low (<200 ng/L) 
and high (≥200 ng/L) NT-proBNP level and calculated a p-value for interaction to test 
whether the difference was significant. In addition, we 1) further adjusted our analyses for 
continuous levels of NT-proBNP and 2) stratified our analyses by a less conservative cut-off 
of low (<400 ng/L) and high (≥400 ng/L) NT-proBNP, was based on relevant guidelines.(15) 
Moreover, we performed additional analyses in which we excluded both participants with 
heart failure hospitalization during follow-up and participants who used loop diuretics at 
baseline, since those participants are likely to suffer from clinical heart failure. Furthermore, 
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we performed several sensitivity analyses in which we separately excluded participants 
who, during follow-up, had 1) a stroke and / or transient ischemic attack (TIA); 2) coronary 
events; 3) atrial fibrillation; 4) cardiovascular events; and 5) a sign of previous myocardial 
infarction (defined as pathological Q or QS-waves on their baseline ECG). In addotion, we 
excluded participants with high cTnT levels (defined conform 99th percentile as hs-cTnT 
levels >0.014 μg/L), to investigate the association of normal levels of cTnT with cognitive 
function and decline. Furthermore, to further investigate whether left ventricular dysfunc-
tion might have confounded our results, we excluded participants using diuretics and 
ace-inhibitors. Supplemental material is available on request. 
Results
Out of the total number of 5,804 PROSPER participants, we excluded n=397 participants with 
missing cTnT measurements. The final sample of the present study included n=5,407 partici-
pants with a mean (standard deviation) age of 75.31 (3.36) years (supplemental figure 1).
Participants with higher cTnT were older, less frequently female and had a higher prevalence 
of hypertension, diabetes mellitus, stroke or transient ischemic attack, myocardial infarc-
tion and vascular disease (all p-values<0.05) (table 1). No difference in total cholesterol, 
high-density lipoprotein and low-density lipoprotein levels were found between the thirds 
of cTnT (all p-values>0.05). Systolic and diastolic blood pressure at baseline were higher in 
participants with higher cTnT levels (both p-values<0.001). Furthermore, participants with 
higher cTnT had a lower eGFR and higher NT-proBNP levels (both p-values<0.001).
The association of cTnT with cognitive function at baseline and cognitive decline during 
follow-up is shown in table 2. At baseline, participants with higher cTnT had worse cogni-
tive function on Stroop test, Letter-Digit Coding test, immediate Picture-Word Learning 
test and delayed Picture-Word Learning test (all p-values<0.05). Longitudinally, participants 
with higher cTnT had a steeper decline on Stroop test, Letter-Digit Coding test, immediate 
Picture-Word Learning test and delayed Picture-Word Learning test (all p-values<0.05). 
Results were independent of cardiovascular diseases or risk factors, since all analyses were 
adjusted for histories of cardiovascular diseases and risk factors thereof. Data on the as-
sociation of cTnT with cognitive function and decline from minimally adjusted models did 
not materially differ from comprehensive adjusted models (supplemental table 1). 
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Figure 1 shows the results of the association of cTnT with cognitive decline, stratified by 
cardiovascular diseases and risk factors. Participants with a history of hypertension had 
a steeper decline on Letter-Digit Coding test and immediate Picture-Word Learning test 
(both p-values for interaction=0.011). 
Table 1. Baseline characteristics of study participants by thirds of cardiac troponin T












Age (years), mean (SD) 74.37 (3.18) 75.17 (3.11) 76.27 (3.44) <0.001
Female, n (%) 1114 (70.3) 977 (49.5) 693 (37.4) <0.001
Education (age left school), mean (SD) 15.14 (1.99) 15.16 (2.22) 15.12 (2.15) 0.829
Pravastatin treatment, n (%) 778 (49.1) 983 (49.8) 921 (49.8) 0.898
Vascular risk factors
History of hypertension, n (%) 952 (60.2) 1202 (61.0) 1199 (64.8) 0.011
History of diabetes mellitus, n (%) 120 (7.6) 209 (10.6) 247 (13.3) <0.001
History of stroke or TIA, n (%) 147 (9.3) 207 (10.5) 248 (13.4) <0.001
History of myocardial infarction, n (%) 140 (8.8) 252 (12.8) 330 (17.8) <0.001
History of vascular disease, n (%) 620 (39.1) 861 (43.7) 916 (49.5) <0.001
Current smoker, n (%) 451 (28.5) 535 (27.1) 441 (23.8) 0.006
Body mass index (kg/m2), mean (SD)* 26.12 (4.38) 26.82 (4.00) 27.41 (4.30) <0.001
Total cholesterol (mmol/L), mean (SD)* 5.71 (0.80) 5.65 (0.89) 5.66 (0.86) 0.112
High density lipoprotein* (mmol/L), mean (SD) 1.29 (0.40) 1.28 (0.44) 1.27 (0.43) 0.404
Low density lipoprotein* (mmol/L), mean (SD) 3.83 (0.80) 3.76 (0.89) 3.77 (0.86) 0.083
Systolic blood pressure (mmHg), mean (SD)* 151.17 (22.29) 155.11 (21.32) 157.39 (22.37) <0.001
Diastolic blood pressure (mmHg), mean (SD)* 82.76 (11.94) 84.02 (11.55) 84.44 (11.62) <0.001
Blood pressure lowering medication, n (%)
Diuretics 572 (36.1) 755 (38.3) 851 (46.0) <0.001
ACE-inhibitors 185 (11.7) 292 (14.8) 409 (22.1) <0.001
Beta-blockers 408 (25.8) 523 (26.5) 462 (25.0) 0.544
Calcium channel blockers 413 (26.1) 475 (24.1) 476 (25.7) 0.334
ApoE genotype 0.783
E2 carriers 14 (0.9) 12 (0.6) 9 (0.5)
E3/E3 carries 984 (62.1) 1226 (62.2) 1123 (60.7)
E4 carriers 389 (24.6) 482 (24.4) 452 (24.4)
Biochemistry, mean (SD)
eGFR (ml/min/m1.73m2) 61.07 (14.33) 60.86 (14.65) 58.24 (14.63) <0.001
NT-proBNP level (ng/L)* # 159.39 (549.23) 230.77 (525.78) 475.51 (542.09) <0.001
Fasting glucose level (mmol/L)*^ 5.41 (1.49) 5.45 (1.25) 5.49 (1.58) 0.362
Abbreviations: SD, standard deviation; n, number; TIA, transient ischemic attack; eGFR, estimated glomerular filtration 
rate; NT-proBNP, N-terminal pro-brain natriuretic peptide. P-values were calculated using the continuous value of the 
square root of troponin levels for continuous variables and Chi-squared tests for categorical variables.
*adjusted p-value for age and sex  #measured at 6 months    ^missing data for n=716 participants
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Figure 2 shows the association of cTnT with cognitive function at baseline in participants 
with low (<200 ng/L) and high (≥ 200 ng/L) NT-proBNP levels. For participants with low NT-
proBNP levels, we observed that higher cTnT was associated with worse cognitive function 
on the Stroop test, Letter-Digit Coding test, immediate Picture-Word Learning test and de-
layed Picture-Word Learning test (all p-values <0.05). Although this trend was less marked 
on all four cognitive function tests for participants with high NT-proBNP levels, there was 
no significant difference between low and high NT-proBNP levels in the association of cTnT 
with cognitive function (all p-values for interaction>0.05). Table 3 shows the longitudinal 
association of cTnT with cognitive decline in participants with low and high NT-proBNP 
levels. Again, a trend was found showing that in participants with low NT-proBNP levels, 
higher levels of cTnT were associated with steeper decline on all four cognitive function 
tests. This association remained significant for the immediate Picture-Word Learning test. 
However, this difference between low and high NT-proBNP levels in the association of cTnT 
with cognitive function was not significant (all p-values for interaction>0.05). When further 
adjusting for continuous levels of NT-proBNP and when stratifying our analyses according 
to the less conservative cut-off of NT-proBNP < and ≥ 400 ng/L, the association between 
cTnT and cognitive function and decline remained essentially the same (supplemental 
tables 2 and 3).  Furthermore, participants with a history of diabetes mellitus had a steeper 
decline in immediate Picture-Word learning test. In addition, the observed associations 
of cTnT with cognitive function and decline did not materially change when excluding 
participants with heart failure hospitalization during follow-up (n=205) and participants 
who used loop diuretics (n=588) (supplemental table 4).
Furthermore, we investigated whether incident cardiovascular diseases might confound 
our results, by performing sensitivity analyses in which we separately excluded participants 
who, during follow-up, had 1) a stroke or TIA (n=378); 2) coronary events (n=575); 3) 
atrial fibrillation (n=507); 4) cardiovascular events (n=872); and finally 5) a sign of previ-
ous myocardial infarction (defined as pathological Q or QS-waves on their baseline ECG) 
(n=1211). In general, exclusion of these participants did not affect the association of 
cTnT with cognitive function and decline (supplemental tables 5 and 6). In addition, we 
investigated the association of normal values of cTnT with cognitive function and decline, 
by excluding participants with cTnT>0.014 μg/L, conform 99th percentile (n=1002). Results 
from these analyses did not essentially differ (supplemental table 7).  Furthermore, when 
we adjusted our results for use of diuretics and ace-inhibitors, our results remained broadly 
similar (data not shown).
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Figure 1. Association of cardiac troponin T with cognitive decline during follow-up, stratified by cardiovascular 
diseases and risk factors
Data represent mean annual change (95% confidence interval) per 1 square root (ng/L) increase of cardiac troponin T 
for each cognitive test, stratified by cardiovascular diseases. Higher annual change indicates less decline in cognitive 
function over time; expect for the Stroop test, where higher annual change means more decline in cognitive function 
over time. P-values were calculated using the interaction term of cardiovascular disease, square root of cardiac troponin 
T, and time. They represent the statistical difference in annual change in cognitive function between participants with 
and without cardiovascular disease or risk factors. Adjusted for age, sex, country, education, treatment with pravastatin 
or placebo and test version where appropriate. 
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Figure 2. Association of cardiac troponin T with baseline cognitive function, stratified by NT-proBNP
Abbreviations: SE, standard error. Higher scores indicate better cognitive performance; expect for the Stroop test, where 
a higher score indicates worse performance.
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Table 2. Association of cardiac troponin T with cognitive function at baseline and during follow-up
Cognitive tests (mean, SE)








Stroop, seconds Baseline score 65.91 (1.16) 67.26 (1.10) 70.09 (1.10) <0.001
Annual change 0.34 (0.12) 0.59 (0.11) 1.06 (0.12) 0.013
LDCT, digits coded Baseline score 23.36 (0.32) 22.94 (0.30) 22.28 (0.30) <0.001
Annual change -0.29 (0.03) -0.34 (0.02) -0.46 (0.03) <0.001
PLTi, pictures remembered Baseline score 9.45 (0.09) 9.36 (0.08) 9.28 (0.08) 0.002
Annual change 0.01 (0.01) -0.02 (0.01) -0.06 (0.01) <0.001
PLTd, pictures remembered Baseline score 10.31 (0.12) 10.09 (0.12) 10.05 (0.11) 0.013
Annual change -0.03 (0.01) -0.06 (0.01) -0.12 (0.02) 0.001
Data represent model-based adjusted means (standard error) of each cognitive function test concerning the baseline 
associations. For the longitudinal analyses, data represent model-based adjusted mean annual change (standard error) 
per 1 square root (ng/L) increase of cardiac troponin T for each cognitive function test. Cardiac troponin T was mea-
sured after  6 months of follow-up. *Adjusted p-values were calculated using the continuous value of the square root 
of troponin levels. Abbreviations: SE, standard error; LDCT, Letter-Digit Coding  test; PLTi, Picture-Word Learning test, 
immediate; PLTd, Picture-Word Learning test, delayed.  
Table 3. Association of cardiac troponin T and NT-proBNP with cognitive decline during follow-up
NT-proBNP








Low (<200 ng/L) N=1254 N=1279 N=826
 Stroop, seconds 0.27 (0.13) 0.64 (0.13) 0.71 (0.17) 0.076
 LDCT, digits coded -0.27 (0.03) -0.34 (0.03) -0.38 (0.04) 0.287
 PLTi, pictures remembered 0.01 (0.01) -0.01 (0.01) -0.05 (0.02) 0.001
 PLTd, pictures remembered -0.02 (0.02) -0.06 (0.02) -0.09 (0.02) 0.176
High (≥ 200 ng/L) N=330 N=693 N=1025
 Stroop, seconds 0.59 (0.29) 0.45 (0.21) 1.48 (0.19) 0.540
 LDCT, digits coded -0.37 (0.06) -0.34 (0.04) -0.53 (0.04) 0.001
 PLTi, pictures remembered 0.01 (0.02) -0.04 (0.02) -0.07 (0.02) 0.070
 PLTd, pictures remembered -0.06 (0.04) -0.06 (0.03) -0.14 (0.02) 0.120
Abbreviations: SE, standard error; n, number; LDCT, Letter-Digit Coding test; PLTi, Picture-Word Learning test, immedi-
ate; PLTd, Picture-Word Learning test, delayed. Data represent model-based adjusted mean annual change (standard 
error) per 1 square root (ng/L) increase of cardiac troponin T for each cognitive function test. Cardiac troponin T and 
NT-proBNP were measured after 6 months of follow-up. *Adjusted p-values were calculated using the interaction term 
of time x square root of troponin levels. 




In this large prospective cohort study, we found that among 5,407 older men and women, 
higher levels of hs-cTnT were associated with worse cognitive function at baseline and 
steeper cognitive decline. Results were independent of cardiovascular diseases or risk fac-
tors. Similar trends were observed in participants with lower NT-proBNP levels below levels 
which might be indicative of clinical heart failure.
Our findings are in line with a previous study by Schneider et al., investigating the associa-
tion of hs-cTnT with cognitive function.(7) This prospective follow-up study, which included 
9,472 community-dwelling participants with a mean age of 63 years, showed that higher 
levels of hs-cTnT were associated with lower scores on a digit symbol substitution test and 
a word fluency test, indicating worse cognitive function. Furthermore, during a median 
follow-up period of 13 years, higher baseline concentrations of hs-cTnT were associated 
with an increased risk for dementia hospitalizations.(7) Although these results did not 
appreciably alter when analyses were additionally adjusted for left ventricular hypertrophy 
and carotid intima media thickness, no information on NT-proBNP was available. In addi-
tion, this study did not consider apolipoprotein E4 genotype, a well-known risk factor for 
the development of cognitive impairment, as a potential confounder in the association 
between hs-cTnT and cognitive function.(18) Another difference between the present 
study and the study by Schneider et al. was the cognitive test battery. Both studies used 
measures of delayed word memory and the digit symbol substitution test, which measures 
processing speed and executive function. The only difference is that the ARIC study used 
the Word Fluency Test, whereas we used the Stroop test, although both measure executive 
function and processing speed. We think it is unlikely that this difference in choice of tests 
is significant enough to make different inferences about the outcome. To our knowledge, 
our study is the first examining the association of hs-cTnT and cognitive function in older 
adults at high cardiovascular risk, which tested the potential role of cardiovascular diseases, 
risk factors and NT-proBNP, and adjusted for apolipoprotein E4 genotype as well.
Several mechanisms can be proposed to explain the association of cTnT with worse cogni-
tive function and steeper cognitive decline. First, cTnT might be a reflection of underlying 
myocardial injury as well as cerebral damage, rather than being causally related. It is well 
known that cardiovascular and cerebrovascular disease share the same risk factors, includ-
ing hypertension, diabetes mellitus and smoking. These risk factors for cognitive decline 
clearly also cause myocardial disease, resulting in increased levels of cTnT. The finding that 
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participants with a history of hypertension and diabetes mellitus had a steeper decline on 
Picture-Word immediate test in stratified analyses, further supports this hypothesis. Sec-
ond, although our results were found in participants without NYHA functional class stage 
III or IV, we do not have echocardiography data to rule out the possibility that higher levels 
of cTnT indicate suboptimal cardiac functioning with subsequent decreased cardiac output 
and cerebral hypoperfusion.(19, 20) Cerebral hypoperfusion has previously been associ-
ated with a higher risk of dementia.(21) However, this explanation is less likely since in the 
current study, participants with NT-proBNP levels <200 ng/L showed the same results, and 
additional adjustment for NT-proBNP levels did not change the results. Third, cTnT might 
have a direct effect in the brain, causing decreased cerebral function. However, no evidence 
has been provided for this explanation yet. Fourth, although it is generally believed that 
cTnT is only expressed in striated muscle cells, animal studies have revealed expression of 
troponin proteins, including troponin T, in smooth muscle cells of rats and mice as well.(22, 
23) In addition, a recent report has shown the existence of cTnT in vascular smooth muscle 
cells of humans, and also found that cTnT contributes to calcium-mediated contraction of 
smooth muscle cells in mice experiments.(24) Although it has been reported that cTnT is 
highly specific for cardiomyocytes, these recent findings suggest that cTnT might also be 
a reflection of smooth muscle cell involvement.(24) Higher levels of cTnT may therefore 
indicate vascular smooth muscle cell damage in an early stage, before the manifestation of 
clinical or even subclinical diseases. This might also explain the observation that higher lev-
els of cTnT are associated with subclinical brain disease, including silent brain infarcts and 
white matter hyperintensities.(5) Speculatively, cTnT is not only released by cardiomyocytes 
but also by smooth muscle cells in the brain vasculature, and may therefore mark structural 
brain damage as a cause of cognitive decline.  
The magnitude of the association between cTnT and cognitive decline we report, is com-
parable in magnitude to associations of known risk factors of cognitive decline, such as 
apolipoprotein E4 carriership, smoking status and history of diabetes, indicating that the 
effects are clinically relevant.
A limitation of this study might be that all participants had cardiovascular diseases or risk 
factors thereof, which might restrict the extrapolation of our findings to a general popula-
tion of older individuals. However, at the same time this is an advantage of our study, since 
it allows us to perform several sensitivity analyses to investigate the influence of cardio-
vascular diseases and risk factors on the association between cTnT and cognitive function. 
Second, although we adjusted our analyses for potential confounders, it is uncertain if this 
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fully accounts for the differences between the troponin groups. In addition, there might 
still be other factors which we did not consider in our analyses. Furthermore, the lack of 
extensive information on cardiac functioning is a weakness of our study. Strength of this 
study is the large sample size of 5,407 participants, who all underwent repeated extensive 
neuropsychological examination including four different cognitive function tests, during a 
mean follow-up period of 3.2 years, and, critically, inclusion and adjustment for NT-proBNP 
measures. Furthermore, cTnT measurements were performed using a high-sensitivity assay, 
which can detect 10-fold lower concentrations than the usual assay, and therefore allows 
detection of already very minor damage of the myocardial tissue. 
Higher levels of hs-cTnT associate with worse cognitive function and steeper cognitive de-
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the iVitality proof-of-principle study
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Background Mobile phone-assisted technologies provide the opportunity to optimize the 
feasibility of long-term blood pressure (BP) monitoring at home, with the potential of 
large-scale data collection. In this proof-of-principle study, we evaluated the feasibility 
of home BP monitoring using mobile phone-assisted technology, by investigating 1) the 
association between study center and home BP measurements; 2) adherence to remind-
ers on the mobile phone to perform home BP measurements; and 3) referrals, treatment 
consequences and BP reduction after a raised home BP was diagnosed.
Methods We used iVitality, a research platform that comprises a Website, a mobile phone-
based app, and health sensors, to measure BP and several other health characteristics 
during a six-month period. BP was measured twice at baseline at the study center. Home 
BP was measured on four days during the first week, and thereafter, at semimonthly or 
monthly intervals, for which participants received reminders on their mobile phone. In the 
monthly protocol, measurements were performed during two consecutive days. In the 
semimonthly protocol, BP was measured at one day.
Results We included 151 participants (mean age (standard deviation) 57.3 (5.3) years). 
BP measured at the study center was systematically higher when compared with home BP 
measurements (mean difference systolic BP (standard error) 8.72 (1.08) and diastolic BP 
5.81 (0.68) mm Hg, respectively). Correlation of study center and home measurements 
of BP was high (R=0.72 for systolic BP and 0.72 for diastolic BP, both p-values<0.001). 
Adherence was better in participants measuring semimonthly (71.4%) compared with 
participants performing monthly measurements (64.3%, p=0.008). During the study, 
41 (27.2%) participants were referred to their general practitioner because of a high BP. 
Referred participants had a decrease in their BP during follow-up (mean difference final 
and initial (standard error) -5.29 (1.92) for systolic BP and -2.93 (1.08) for diastolic BP, both 
p-values<0 .05). 
Conclusion Mobile phone-assisted technology is a reliable and promising method with 
good adherence to measure BP at home during a six-month period. This provides a possibil-
ity for implementation in large-scale studies and can potentially contribute to BP reduction.




High blood pressure contributes to the global burden of disease, accounting for 9.4 million 
deaths per year.(1) With a prevalence as high as 78% among the 65-plus population in 
Europe, it is one of the most common chronic conditions in primary care.(2) Although the 
prevalence is predicted to further increase over the coming years, only 70% of all hyperten-
sive patients are aware of having hypertension.(3, 4) In spite of widely available effective 
ways to reduce blood pressure, rates of hypertension control are still far from optimal.(2, 
5-7) In one study including 5,296 participants, blood pressure control was achieved in only 
30% of patients, who were aged 60 years or older.(8)
The increasing availability of the Internet, mobile phones, and health sensors provides the 
potential to interactively administer health interventions at home. Recent surveys show 
that at least 75% of the European population uses the Internet on a regular basis, with 
almost half of them using a mobile phone to access the Internet (smartphone).(9) Adults 
aged 65 years and older are the fastest-growing group of Internet users.(10) Older adults 
have a high interest in self-assessment health tools.(11) This enables people to measure 
blood pressure at home, with the potential of direct feedback and treatment adjustments. 
Furthermore, previous studies show that home blood pressure measurements, when com-
pared with clinic blood pressure measurements, are in fact a stronger prognostic indicator 
of cardiovascular events.(12-14) It could therefore be effective to identify patients at risk of 
cardiovascular events and thereby prevent the occurrence of cardiovascular complications.
(12, 15) In addition, it provides a potential for large-scale implementation and data collec-
tion. However, data on feasibility of long-term home blood pressure measurements, using 
the Internet and mobile phones, are scarce.(16-18)
The aim of this proof-of-principle study was to evaluate home blood pressure measure-
ments using mobile phone-assisted technology. For this, we investigated 1) the association 
between study center and home blood pressure; 2) the adherence to perform home blood 
pressure measurements according to a monthly or semimonthly measurement protocol; 
and 3) referrals, treatment consequences and blood pressure reduction after a raised home 





iVitality is a Web-based research platform that consists of a Website, a mobile phone-
based app, and sensors that are connected with or already integrated in the mobile phone 
to measure blood pressure.(19) This iVitality study is a proof-of-principle study in which 
participants were randomized to perform home blood pressure measurements according 
to a monthly or semimonthly measurement protocol, during a period of six months. The 
different measurement protocols are described in more detail in the “Follow-Up Measure-
ments” paragraph below.
We chose to perform this study in people with a parental history of dementia because 1) 
they have a higher risk of both hypertension and dementia, making them a potentially 
suitable target group for large-scale preventive studies and 2) they are highly motivated 
to participate in preventive studies.(13, 14, 15) Other inclusion criteria were 1) age 50 
years and older; 2) familiar with and in possession of a mobile phone with iOS or Android 
(version, 2.3.3 or higher) software; and 3) motivated to measure health characteristics at 
home several times a month, during a six-month period. Exclusion criteria were a medical 
diagnosis of dementia and/or any other cognitive disorder and a medical history of stroke 
and/or transient ischemic attack.
Participants were recruited through advertisements in memory outpatient clinics, nurs-
ing homes, general practices, and on the Website, and in the newsletter of the Dutch 
Alzheimer Foundation (Alzheimer-Nederland). If all of the inclusion criteria were met, 
participants received detailed study information in print. They visited the study center at 
Leiden University Medical Center or Academic Medical Center Amsterdam at baseline, 
where they received information about the study and baseline measurements were per-
formed by a study physician or research nurse. Written informed consent was obtained 
from all participants. The medical ethical committee of Leiden University Medical Center, 
the Netherlands, approved the study.
Baseline measurements
Enrolment and follow-up took place from September 2013 to January 2015. In preparation 
for the first visit to the study center, all participants completed a Web-based question-
naire on education, medical history, and medication use. During the visit to the study 
center, detailed information about the iVitality app and instructions on how to use it were 
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given. History of hypertension and medication use was self-reported. Blood pressure was 
measured twice at baseline on the upper left arm, in sitting position with a fully automatic 
electronic blood pressure monitor. Participants were instructed in the use of the home 
blood pressure monitor.
Follow-up measurements
During a six-month period, participants received automatic messages on preprogrammed 
days at self-chosen time points on their mobile phone, which reminded them to measure 
blood pressure. Participants with an Android mobile phone used an A&D blood pressure 
monitor (A&D Company, Ltd; model UA 767 Bluetooth) which was connected to the mo-
bile phone and automatically transferred the results to the iVitality app by Bluetooth.(20) 
Participants with an iPhone used an OMRON (OMRON Healthcare Company, Ltd, model 
M6W and M6AC (HEM-7322-E)); they manually typed their blood pressure values and 
heart rate in the iVitality app.(21) During the first week and the last week of the study, 
all participants performed blood pressure measurements according to the guideline of 
the European Society of Hypertension.(13) In short, participants were asked to measure 
their blood pressure twice at both morning and evening, at least for four days during 
the first week of the study, with day one being discarded.(13) For the rest of the study 
period, blood pressure was measured according to two different study protocols, to which 
participants were randomly assigned by a computerized program at baseline. Randomiza-
tion was performed in a 1:1 manner stratified for sex. In the monthly protocol, participants 
performed measurements in the morning and evening of two consecutive days. In the 
semimonthly protocol, blood pressure was measured in the morning and evening of only 
one day. Blood pressure was measured twice at each measurement; the mean of both 
measurements was used. Reminders to perform blood pressure measurements were sent 
the evening before the measurement day and at the actual day on which the participant 
was expected to perform the blood pressure measurements. When participants did not 
perform their blood pressure measurements, they received a reminder the day after. This 
reminder was sent automatically by the Website of the iVitality research platform, and 
therefore, was a standardized procedure. The measured blood pressure was sent as a 
message to the mobile phone. Blood pressure measurements were also graphically visible 
in the app. Participants with a mean systolic home blood pressure above 135 mm Hg and/
or 85 mm Hg for diastolic home blood pressure during these days were considered as 




Characteristics of the study participants are reported as mean with standard deviation 
for continuous variables and as number with percentage for categorical variables. We 
used Pearson’s correlation coefficient to calculate the correlation between home and study 
center blood pressure measurements. To investigate agreement between study center and 
home blood pressure measurements, we computed the mean and the difference in study 
center and home blood pressure measurements and visualized this in a Bland–Altman plot. 
Adherence was defined as the actual performance of all blood pressure measurements 
within one week of the time point they were expected to perform their measurements 
and for which the participant received reminders through the mobile phone app. For each 
participant, we calculated the percentage of adherence during follow-up. Difference in ad-
herence between the monthly and semimonthly measurement protocol was assessed using 
a Mann–Whitney U test. In this proof-of-principle study, only participants who completed 
the six-month period were used in the primary analysis. In a sensitivity analysis, we included 
all participants who were included at baseline. 
We investigated the difference in blood pressure during the first week and the final week 
after six months using a paired t-test. For both blood pressure during the first week and 
final blood pressure, we calculated the mean values of all blood pressure measurements 
performed during the first and last week, with day one of both weeks being discarded.
(13) All analyses were performed using SPSS (version 22.0.0, SPSS Inc., Chicago, IL, USA).
Results 
Figure 1 shows the inclusion flowchart of participants. A total of 195 participants registered 
on the Web to participate. Of those, 27 did not meet inclusion criteria and 17 registered 
after recruitment had been completed because of a time lag between registration on the 
Web and baseline visits. Our study population therefore included 151 participants. A num-
ber of 66 (43.7%) participants were assigned to perform blood pressure measurements at 
a monthly interval; 85 (56.3%) participants were assigned to perform semimonthly blood 
pressure measurements (figure 1).
Baseline characteristics are shown in table 1. Mean age was 57.3 (standard deviation 
(SD) 5.3) years; 107 (70.9%) participants were female. Of all participants, 56 (37.1%) 
used iPhone and 59 (39.1%) used Samsung. Mean systolic and diastolic blood pressure 
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measured at the study center was 137.8 (SD 18.2) and 85.4 (SD 10.8) mm Hg, respectively. 
Participants within the monthly protocol had a higher body mass index, systolic blood pres-
sure, and diastolic blood pressure at baseline (data not shown). A number of 32 (21.2%) 
participants had a history of hypertension and used antihypertensive medication, most 
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Figure 1. Flowchart of study participants
*reasons why participants did not meet in-/exclusion criteria were as follows: n=4 did not have the correct software version of 
the smartphone; n=6 did not have parents with dementia; n=6 were on holidays during the inclusion period; n=7 were not 


































N=27 did not meet in-/exclusion criteria*
N=17 registered after inclusion was complete
Figure 1. Flowchart of study participants
*reasons why participants did not meet in-/exclusion criteria were as follows: n=4 did not have the correct software 
version of the smartphone; n=6 did not have parents with dementia; n=6 were on holidays during the inclusion period; 
n=7 were not interested to participate after reading the study information; n=4 because of other reasons.
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commonly diuretics (15 participants (46.9% of hypertensive participants)). This did not 
differ between the monthly and semimonthly protocol.




Age (years) 57.3 (5.3)
Female, n (%) 107 (70.9%)
Body mass index 26.4 (4.0)




Study center, n (%)
Academic Medical Center Amsterdam 55 (36.4%)
Leiden University Medical Center 96 (63.6%)






Systolic blood pressure (mmHg) 137.8 (18.2)
Diastolic blood pressure (mmHg) 85.4 (10.8)
Heart rate (beats per minute) 67.2 (10.2)
Vascular risk factors, n (%)
History of hypertension 32 (21.2%)
History of diabetes mellitus 2 (1.3%)
History of MI 4 (4.6%)
History of arrhythmia 11 (7.3%)
History of heart failure 3 (2.0%)
Hypercholesterolemia 14 (9.3%)
Current smoker 14 (9.3%)




Calcium antagonists 6 (4.0%)
Other 9 (6.0%)
N. of antihypertensive medication, n (%)
One 21 (65.6%)
Two or more 11 (34.4%)
Data represent mean (standard deviation) unless stated otherwise. Abbreviations: n, number; MI, myocardial infarction; 
MMSE, mini-mental state examination.  *Missing data for n=3 participants. Low: primary education, lower educa-
tion, MAVO/MULO. Intermediate: high general secondary education (HAVO, HBS), Preparatory Scientific Education 
(VWO), intermediate professional education (MBO). High: higher professional education (HBO), academic education 
(university).
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The association between study center and home blood pressure during the first week is 
shown in figure 2. The correlation between study center and home measurements was 
high for both systolic (R=0.72, p-value<0.001) and diastolic blood pressure (R=0.72, p-
value<0.001, panel A). Systolic blood pressure at the study center was systematically 8.72 
mm Hg higher (standard error (SE) 1.08) and diastolic blood pressure was 5.81 (0.68) 
mm Hg higher when compared with home blood pressure measurements (panel B). The 
Bland–Altman plot shows that the difference between the measurements was randomly 
distributed over the mean of the measurements, indicating that there was no systematic 
bias in agreement between the study center and home measurements. The 95% limits of 
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Figure 2. Association between blood pressure measurements at home and in the study center
Abbreviations: R, Pearson’s correlation coefficient; SBP, systolic blood pressure; DBP, diastolic blood pressure. 
Panel A shows the home blood pressure (mean of two consecutive measurements in both morning and evening at day 2, 3 and 
4, x-axis) and corresponding study center blood pressure measurements (mean value of two consecutive measurements, y-
axis) for each participant. Panel B shows the agreement between study center and home systolic and diastolic blood pressure 
measurements. 
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Figure 2. Association between blood pressure measurements at home and in the study center
Abbreviations: R, Pearson’s correlation coefficient; SBP, systolic blood pressure; DBP, diastolic blood pressure. 
Panel A shows the home blood pressure (mean of two consecutive measurements in both morning and evening at 
day 2, 3 and 4, x-axis) and corresponding study center blood pressure measurements (mean value of two consecutive 
measurements, y-axis) for each articipant. Panel B shows the agreem nt between study center and home systolic and 
diastolic blood pressure measurements. 
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agreement for the comparison were −16.82 to 32.82 mm Hg for systolic blood pressure 
and −9.71 to 21.33 mm Hg for diastolic blood pressure.
Adherence to the monthly and semimonthly blood pressure measurement protocols is 
shown in figure 3. In total, 12 participants did not complete follow-up: 5 (7.6%) partici-
pants in the monthly measurement protocol and 7 (8.2%) participants in the semimonthly 
measurement protocol. Median adherence to perform blood pressure measurements was 
71.4% (figure 3). Participants performing semimonthly blood pressure measurements were 
more adherent (median adherence 71.4%) when compared with participants performing 
monthly blood pressure measurements (64.3%, p-value=0.008). There was no difference 
in adherence between participants who entered their blood pressure measurements manu-
ally and participants who used a Bluetooth connection to transfer the measurements (data 
not shown). Furthermore, a sensitivity analysis in which we investigated the adherence of 
all 151 participants who were included at baseline, showed similar results: adherence was 
higher in participants who performed semimonthly blood pressure measurements (median 
adherence 85.7%) when compared with participants performing monthly measurements 
(71.4%, p-value=0.002, data not shown). Discontinuation was highest within the first 
weeks of follow-up for both measurement protocols.
Table 2 presents the difference in final and initial home blood pressure measurements. 
Among all participants, there was no difference between final and initial blood pressure, for 
both systolic (mean difference (SE) -1.30 (1.10) mm Hg, P=.240) and diastolic (-0.90 (0.51) 
Figure 3. Adherence of participants to monthly and semi-monthly measurement protocol
Data represent the percentage of participants who are adherent to perform the expected blood pressure measure-
ments.
































































































































































































































































































































































































































































































































































































































mm Hg, p-value=0.081) blood pressure. There were 41 out of 151 (27.2%) participants 
who were referred to their GP because of a high blood pressure, of whom 35 (85.2%) 
actually visited their GP. In referred participants, blood pressure decreased significantly 
during the study, both systolic (mean difference (SE) -5.29 (1.92) mm Hg, p-value=0.011) 
and diastolic (-2.93 (1.08) mm Hg, p-value=0.012). Furthermore, no difference was found 
between final and initial blood pressure for both systolic and diastolic blood pressure 
between the monthly and semimonthly protocol (data not shown). In 7 out of 41 (17.1%) 
participants, blood pressure lowering medication had been started or changed.
Discussion 
This proof-of-principle study, in which we evaluated the feasibility of home blood pres-
sure measurements during a six-month intervention period using mobile phone-assisted 
technology, has three main findings. First, study center and home blood pressure were 
highly correlated, although blood pressure measured at the study center was systematically 
higher when compared with home blood pressure. Second, adherence of all participants 
to perform blood pressure measurements was high and persisted during six months with 
better adherence in participants measuring semimonthly compared with participants who 
performed monthly measurements. Third, in participants who were referred to their GP be-
cause of a high blood pressure, systolic and diastolic blood pressure decreased significantly 
during the study, especially for those who started medication.
Our finding that  systolic and diastolic blood pressure at the study center was systematically 
higher when compared with home blood pressure measurements is in line with previous 
literature.(22) A well-known explanation for this is the “white-coat effect”, meaning that 
blood pressure is higher because of stress and anxiety that patients experience during a 
clinical setting.(22, 23) Literature shows that home blood pressure measurements, instead 
of office or clinic blood pressure measurements, are in fact a stronger prognostic indicator 
of cardiovascular events and even have their own (lower) reference values.(12-14) A partic-
ipant-level meta-analysis including 5,008 participants (mean age 57 years, not treated with 
antihypertensive medication), showed that in participants with an optimal office blood 
pressure (<120/<80 mm Hg), a 10-mm Hg higher systolic home blood pressure increased 
the risk of any cardiovascular event by nearly 30%.(12) In addition, previous studies on 
cost-effectiveness show that compared with usual care, home blood pressure monitoring 
is very useful for reducing health care costs. In view of the low burden of measuring and 
established treatment options, home blood pressure monitoring could therefore be an 
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important strategy to further prevent cardiovascular complications, especially in people at 
risk.(13)
Previous studies on adherence to perform home blood pressure measurements show simi-
lar results to our findings.(17, 24) In a study on telemonitoring including 213 hypertensive 
patients, who were asked to measure their blood pressure at least six times a week during 
six months, mean adherence was 73%.(17) Another study including only patients with 
heart failure (mean age 61 years) showed adherence of 55%.(24) Furthermore, in this 
study, we found that participants using the semimonthly measurement protocol showed 
higher adherence compared with participants using the monthly measurement protocol. 
A possible explanation could be that the fact that participants received a reminder twice 
a month (instead of once a month), might have kept participants more engaged in the 
study and therefore increased their adherence.(19) Furthermore, the burden of measuring 
for one day every two weeks may have been perceived lower than measuring during two 
consecutive days, albeit with monthly intervals.
Home-based blood pressure measurements using mobile phone-based technology may 
have several potential opportunities. First, other parameters derived from repeated blood 
pressure measurements, can easily be calculated, especially in a home-based setting. An 
example of such a parameter is blood pressure variability, of which we recently showed 
its association with cognitive decline.(25) Second, the combination with other parameters 
and measurements may reveal additional targets for blood pressure control. Physical activ-
ity, sleep, and other lifestyle factors can be measured using a mobile phone. This offers 
the potential for interventions, for instance aimed at increasing physical activity, that also 
beneficially affect blood pressure. The iVitality platform offers the opportunity to assess 
these lifestyle factors. Third, mobile phone-based technology might be a cost-effective 
alternative in the control of hypertension. It was previously shown that ambulatory blood 
pressure monitoring as a diagnostic strategy for hypertension saves costs, mainly because 
additional costs from ambulatory monitoring are counterbalanced by cost savings from 
better targeted treatment.(26) As mobile phone-based technology only requires a standard 
blood pressure monitor, which is much cheaper when compared with an ambulatory blood 
pressure monitor, we believe it has the potential of saving health care costs.
In our study, blood pressure was lower at the end of follow-up when the participant was 
referred to the GP because of a high blood pressure at baseline. There are two possible 
explanations for this finding. First, the decrease in blood pressure may be the result of 
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regression to the mean. This phenomenon occurs when repeated measurements tend to 
be followed by measurements that are closer to the mean. Although our baseline measure-
ments were defined on repeated blood pressure measurements, it is still expected that 
the mean blood pressure during follow-up will go down, owing to regression toward the 
mean. Second, it may reflect a true effect of monitoring and subsequent treatment of 
blood pressure. Blood pressure lowering interventions by the GP and higher awareness of 
participants may all have contributed to a lower blood pressure. Although the fact that 
the effect on blood pressure was highest in those who initiated medication suggests the 
second explanation, we have not collected enough information on interventions in this 
proof-of-principle study to draw definite conclusions. An adequately powered randomized 
controlled trial may help to establish the effects of the interventions.
For this proof-of-principle study, we selected highly motivated participants with a parental 
history of dementia. This may have introduced a selection bias toward better adherence 
and treatment effects, which reduces the external validity for other, broader defined popu-
lations. The strength of this study is that mobile phone technology was used to collect 
study data on blood pressure. This innovative method reduces the need for face-to-face 
contact and stimulates self-management. Now that this proof-of-principle study is promis-
ing, broader and larger populations can be included in future studies.
This proof-of-principle study demonstrates that mobile phone-assisted technology can be 
used as a reliable and promising method to measure blood pressure at home during a 
six-month period. This provides a possibility for implementation in large-scale studies and 
can potentially lead to blood pressure reduction and eventually reduction of cardiovascular 
disease.
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This thesis aimed to 1) further investigate whether blood pressure in older people is a risk 
factor for cardiovascular events and cognitive impairment; 2) study whether early markers 
of cardiac disease are related with cognitive impairment; and 3) to evaluate the feasibility 
of home blood pressure monitoring using smartphone-assisted technology, which might 
eventually assist to prevent cognitive impairment.
Main findings
The first part of this thesis consists of three studies that evaluated the association of blood 
pressure and blood pressure variability with cardiovascular events and cognitive function 
in older age. In chapter 2, we investigated the association of blood pressure with the risk 
of cardiovascular events. We found that the association of diastolic blood pressure with 
cardiovascular events in older people varied upon cardiovascular history: in participants 
without a history of cardiovascular disease, there was no association between diastolic 
blood pressure and cardiovascular events, whereas participants with a cardiovascular his-
tory showed a decreased risk of cardiovascular events with higher diastolic blood pressure. 
Chapter 3 assessed the association between visit-to-visit blood pressure variability and 
cognitive function in older people. Visit-to-visit blood pressure variability has previously 
been related to cerebrovascular damage. We showed that higher visit-to-visit systolic and 
diastolic blood pressure variability, independent of average blood pressure, was associated 
with worse cognitive function. Furthermore, we found that higher blood pressure variability 
was related to lower hippocampal volume and higher risk of cortical infarcts and cerebral 
microbleeds. We hypothesized that blood pressure lowering medication might mediate 
the association of blood pressure variability with cognitive function, possibly through its 
previously found effect on blood pressure variability.(1) In chapter 4, we found that use 
of beta-blockers and inhibitors of the renin-angiotensin system was associated with higher 
systolic blood pressure variability. However, the association between blood pressure vari-
ability and cognitive impairment was not mediated by blood pressure lowering medication. 
This strengthens the finding that blood pressure variability, independent of blood pressure 
lowering medication, is associated with cognitive impairment.
The second part of this thesis consists of two studies that addressed the association be-
tween early markers of cardiac disease and cognitive function. In chapter 5, we presented 
an association of N-terminal pro-brain natriuretic peptide (NT-proBNP), a neurohormone 
that is commonly used in the diagnosis of clinical heart failure, with worse cognitive func-
tion and steeper cognitive decline. Chapter 6 showed that participants with high but 
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within normal ranges levels of cardiac troponin T (cTnT), routinely used in the diagnosis of 
acute myocardial infarction, had worse cognitive function and steeper cognitive decline. 
These results were independent of cardiovascular diseases or risk factors. Furthermore, 
similar trends were found in participants with lower NT-proBNP levels below which might 
be indicative of clinical heart failure, suggesting that hs-cTnT is an independent predictor 
of cognitive impairment.
In the last part of this thesis, we introduced the innovative research technology iVital-
ity, which comprises a website, a smartphone-based application and health sensors to 
measure health characteristics at home (chapter 7). In a proof of principle study includ-
ing 151 people, we evaluated the feasibility of home blood pressure monitoring using 
iVitality during six months. We showed a high correlation between office and home blood 
pressure measurements. In addition, adherence of participants to perform blood pressure 
measurements was high. Furthermore, we found a significant decrease in home blood 
pressure when participants were referred to their general practitioner in case of a high 
blood pressure. We therefore concluded that smartphone-based technology is a reliable 
and promising method with good adherence. This provides a possibility for implementation 
in large-scale studies and can potentially contribute to blood pressure reduction, eventually 
helping to prevent cognitive impairment. 
Discussion
Previous studies showed that the association between high diastolic blood pressure and 
increased risk of cardiovascular events attenuated with older age, and even reversed in the 
oldest old or biologically old.(2-7) Our finding that low blood pressure associates with a 
higher risk of cardiovascular events in people with previous cardiovascular disease further 
supports the hypothesis that in older people, biological or vascular age might be more im-
portant than calendar age per se. In this manner, low diastolic blood pressure, which is an 
important contributor of the perfusion pressure of an organ, might predispose to vascular 
hypoperfusion of vital organs, particularly in people who already suffer from increased 
arterial stiffness or obstruction.(8, 9) Besides average blood pressure, we showed that 
variability in sufficiently high blood pressure might be important in older people, especially 
concerning cognitive function. 
Blood pressure variability may reflect a long-term hemodynamic instability in the sys-




stress may lead to endothelial dysfunction and micro-vascular damage with consequent 
alterations in brain structure and function.(12) Furthermore, exaggerated fluctuations 
in systemic blood pressure could result in repeated episodes of cerebral hypoperfusion 
causing neuronal injury and cell death, particularly in vulnerable brain regions such as the 
hippocampus.(13) Blood pressure management in older people might therefore be more 
complicated then what current guidelines include. In addition, a conservative approach in 
the treatment of high blood pressure in older people might be appropriate, especially in 
those with a cardiovascular history. All this underlines the importance of an individualized 
approach in blood pressure management, in particular for older people. 
Our findings that NT-proBNP and cTnT associate with worse cognitive function and decline, 
is in line with earlier studies which suggest a connection between cardiac function and brain 
structures. A possible explanation might be that higher NT-proBNP and cTnT levels indicate 
suboptimal left ventricular functioning with subsequent decreased cardiac output and cere-
bral hypoperfusion.(14) Cerebral hypoperfusion has previously been associated with a higher 
risk of dementia.(15) In line with this, earlier studies showed that patients with clinical heart 
failure have an increased risk of cognitive impairment, and that patients following cardiac 
transplantation showed an improvement in cognitive function.(16-20) Nevertheless, the 
finding that in participants with NT-proBNP levels within the normal range and below those 
indicative of clinical heart failure, cTnT was also associated with worse cognition, merits 
further speculations on underlying pathways. Although it is generally believed that cTnT is 
only expressed in striated muscle cells, animal studies have revealed expression of troponin 
proteins, including troponin T, in smooth muscle cells of rats and mice as well.(21, 22) This 
suggest that cTnT might also be a reflection of smooth muscle cell involvement.(23) Higher 
levels of cTnT may therefore indicate vascular smooth muscle cell damage in an early stage, 
before the manifestation of clinical or even subclinical diseases. This might also explain the 
observation that higher levels of cTnT are associated with subclinical brain disease, including 
silent brain infarcts and white matter hyperintensities.(24) Speculatively, cTnT is not only 
released by cardiomyocytes but also by smooth muscle cells in the brain vasculature, and 
may therefore mark structural brain damage as a cause of cognitive decline. These findings 
emphasize that people with early signs of cardiac or vascular disease are already at increased 
risk of cognitive impairment. Furthermore, it supports the importance of early recognition 
and treatment of cardiovascular risk factors in the prevention of cognitive decline. 
The findings of this thesis strengthen the potential to prevent cognitive decline by early 
control of  modifiable risk factors, including blood pressure, blood pressure variability and 
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cardiac or vascular disease. Since treatment of early stages of cognitive impairment or 
dementia is still lacking, prevention is currently the only option to diminish the burden of 
these disorders. Recently, it has been shown that elevated blood pressure as measured in 
the home situation is a stronger prognostic indicator of cardiovascular events than elevated 
office blood pressure.(25-27) In view of the cost-effectiveness, the low burden of measur-
ing, and manifold established treatment options, home blood pressure monitoring could 
therefore be an important strategy to further prevent cardiovascular complications, includ-
ing cognitive disorders and dementia.(28) The evidence of the last part of this thesis, in 
which we showed that smartphone-assisted technology is a reliable and promising method 
with good adherence to measure blood pressure at home, offers new opportunities. 
Future perspectives
The work described in this thesis tried to provide new insights in the relation of blood pres-
sure and cardiac function with cognitive impairment. Most of the data in this study were 
obtained from the PROspective Study of Pravastatin in the Elderly at Risk, a randomized, 
double blind, placebo controlled trial with a mean follow-up period of 3.2 years. The lon-
gitudinal nature of this study provided the opportunity to study relations between (changes 
in) determinants and subsequent changes in cognitive function. However, a limitation of 
the design used in our studies, is the observational nature, which does not allow to make 
conclusions about causality. 
As for the association between diastolic blood pressure and cardiovascular events, it could 
be that both low diastolic blood pressure and cardiovascular events share a common cause, 
which most likely would be aging of the arterial system, including atherosclerosis. Previous 
studies showed that progression of atherosclerosis is accompanied by a decrease in dia-
stolic blood pressure.(29, 30) Instead of being causally related, low diastolic blood pressure 
might therefore be a reflection of widespread atherosclerosis, which itself associates with 
increased risk of cardiovascular disease and mortality. Another possibility might be that low 
diastolic blood pressure is a reflection of deteriorating health status, leading to increased 
risk of cardiovascular events and mortality.(31) So far, only one randomized controlled 
trial investigated whether older people benefit from higher blood pressure values. The 
Discontinuation of Antihypertensive Treatment in Elderly People  (DANTE) study examined 
whether discontinuation of antihypertensive medication in patients aged 75 years or older 
decreased the risk of cognitive decline.(32) In 385 participants with mild cognitive deficits, 
they found no differences in cognitive, psychological or general daily functioning during 




selection of participants with relatively intact cerebral autoregulation might explain the 
lack of effect of the discontinuation of antihypertensive medication. Future randomized 
controlled trials should include longer follow-up and biologically older people with im-
paired autoregulation. Furthermore, although most trials study the effect of medication, 
the focus of research in older people should be whether discontinuation of medication 
results in better outcomes.
Doubts on the causal nature also holds for the relation between blood pressure variability 
and cognitive impairment: both could stem from a common cause, for instance cardiovas-
cular risk factors, without themselves being related. In line with this, previous literature 
showed that cardiovascular and cerebrovascular disease share the same risk factors, includ-
ing hypertension, diabetes mellitus and smoking.(16, 20) In addition, increased levels of 
cTnT and NT-proBNP might reflect underlying myocardial damage caused by cardiovascular 
risk factors, which themselves also cause cognitive decline.(16, 17) Therefore, random-
ized controlled trials could help to draw conclusions about causality and interventions to 
prevent cerebral damage. These trials should examine whether lowering blood pressure 
variability, for example by calcium-channel blockers, an effective drug-class in lowering 
blood pressure variability, diminishes the risk of cognitive impairment. Furthermore, to 
unravel biological mechanisms concerning cerebral autoregulation, future investigations 
should examine the role of blood pressure variability, NT-proBNP and cTnT with respect to 
perfusion, volumes and small vessel disease of the brain. 
Finally, we showed the feasibility of home blood pressure measurements using smartphone-
assisted technology during six months of follow-up. Results of this study are promising in 
light of an alternative research method to study relevant health characteristics at home. Be-
sides blood pressure, new technologies allow home-based measurement of other lifestyle 
characteristics, such as physical activity, blood glucose concentration, gait speed and sleep 
parameters. Furthermore, this also provides interesting opportunities for implementation in 
prevention programs, in particular in a primary care setting. In addition, engaging people 
to measure their own health could further stimulate awareness and  involvement. This 
might contribute to a more home-based, self-management approach, which is a welcom-
ing alternative for the current hospital centered paradigm. Future studies should therefore 
investigate the potential of smartphone-assisted technology to prevent or manage cardio-
vascular risk factors and whether this results in less events. Eventually, this might lead to a 
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Door de toename in levensverwachting stijgt het aantal ouderen met cognitieve stoornis-
sen. Het aantal mensen dat wereldwijd lijdt aan dementie zal de komende 20 jaar naar 
verwachting verdubbelen; in 2030 wordt het aantal mensen met dementie geschat op 
65.7 miljoen, in 2050 ligt dit rond de 115.4 miljoen.(1) De afgelopen jaren is in toene-
mende mate aangetoond dat cardiovasculaire risicofactoren bijdragen aan het ontstaan 
van cognitieve stoornissen.(2-4) Met name bij mensen van middelbare leeftijd hebben 
studies laten zien dat cardiovasculaire risicofactoren het risico op hersenveroudering en 
cognitieve stoornissen op oudere leeftijd verhogen.(2, 5) Dit is met name het geval bij 
mensen van middelbare leeftijd; bij oudere mensen wordt deze relatie veel minder sterk 
aangetoond.(6) Het is tot nu toe onduidelijk welk onderliggend mechanisme de relatie 
tussen cardiovasculaire risicofactoren en cognitieve achteruitgang kan verklaren.
Een voorbeeld van een cardiovasculaire risicofactor op middelbare leeftijd die geassocieerd 
is met cognitieve stoornissen op oudere leeftijd, is het hebben van een hoge bloeddruk.
(7) Verschillende studies tonen aan dat een hoge bloeddruk op middelbare leeftijd een 
risicofactor is voor cardiovasculaire ziekten, hersenatrofie en cognitieve achteruitgang.
(8-11) Een aantal gerandomiseerde klinische studies laat daarnaast zien dat bloeddrukver-
lagende medicatie het risico op cognitieve stoornissen vermindert.(12, 13) Recent bewijs 
toont echter dat deze relatie afneemt met toenemende leeftijd; en dat op oudere leeftijd 
een lage bloeddruk juist gerelateerd is aan een hoger risico op cardiovasculaire ziekten 
en cognitieve achteruitgang.(5, 14-16) Deze studie toont ook dat het voornamelijk de 
mensen met een hoge biologische leeftijd zijn, die meer nadelen ondervinden van een lage 
bloeddruk.(17-19)
Behalve bloeddruk is hartschade gerelateerd aan een hoger risico op cognitieve stoornissen 
en dementie. Patiënten met een coronaire hartziekte, boezemfibrilleren en chronisch hart-
falen hebben een slechtere cognitie en een hoger risico op het ontwikkelen van dementie.
(3, 20-22) Deze bevindingen kunnen verklaard worden door een verminderde hartfunctie 
wat leidt tot een verminderde perfusie van de hersenen en een verstoring van de toevoer 
van zuurstof en voedingsstoffen naar de hersenen.(3) Daarnaast is aangetoond dat bij pati-
enten met ernstig hartfalen, de cognitieve functies verbeterden na een harttransplantatie.
(23, 24) Het is nog onduidelijk of mensen met vroege tekenen van hartschade ook een 
verhoogd risico hebben op cognitieve achteruitgang. 
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Doel van dit proefschrift
Dit proefschrift heeft tot doel 1) te onderzoeken of bloeddruk bij oudere mensen een 
risicofactor is voor het optreden van cardiovasculaire ziekten en cognitieve stoornissen; 2) 
te analyseren of vroege markers van hartziekte gerelateerd zijn aan cognitieve stoornissen; 
en 3) te evalueren of smartphone-technologie bruikbaar is bij het langdurig monitoren 
van bloeddruk gemeten in de thuissituatie, met als uiteindelijk doel om hersenschade en 
cognitieve achteruitgang te voorkomen.  
Overzicht van het beschreven onderzoek
Het eerste deel van dit proefschrift bevat drie studies die de relatie tussen bloeddruk en 
variabiliteit in bloeddruk met cardiovasculaire ziekten en cognitieve functie bij oudere men-
sen tonen. In hoofdstuk 2 toonden we aan dat de relatie tussen diastolische bloeddruk 
en cardiovasculaire ziekten bij oudere mensen afhangt van cardiovasculaire ziekten in de 
voorgeschiedenis. Bij mensen zonder een cardiovasculaire voorgeschiedenis, vonden we 
geen relatie tussen diastolische bloeddruk en het optreden van cardiovasculaire ziekten. 
Bij mensen met cardiovasculaire ziekten in de voorgeschiedenis vonden we een lager risico 
op het opnieuw optreden van cardiovasculaire ziekten bij een hogere bloeddruk. Dit komt 
overeen met studies die deze relatie eerder onderzochten en aantoonden dat de ‘oudste 
ouderen’ een lager risico op cardiovasculaire ziekten hadden bij een hogere diastolische 
bloeddruk.(5, 14, 15, 17, 25, 26) Bovendien sluit het aan bij de hypothese dat een lage 
diastolische bloeddruk, welke een belangrijke bijdrage aan de perfusie van een orgaan 
levert, leidt tot vasculaire hypoperfusie van een orgaan, voornamelijk bij mensen die al aan 
arteriële vaatstijfheid lijden. Dit zou kunnen resulteren in een meer voorzichtige aanpak 
van de behandeling van hoge diastolische bloeddruk bij oudere mensen met een voorge-
schiedenis van cardiovasculaire ziekten. Gerandomiseerde onderzoeken die bestuderen of 
een verhoging van diastolische bloeddruk, door bloeddrukverlagende medicatie (deels) 
te staken, leidt tot minder cardiovasculaire ziekten bij mensen met een hoger vasculaire 
leeftijd, zouden hier meer inzicht in kunnen geven. Daarnaast zijn MRI-studies nodig die 
meer inzicht kunnen geven in biologische mechanismen, zoals bijvoorbeeld cerebrale 
hypoperfusie, die deze relatie kunnen verklaren. Hoofdstuk 3 toonde aan dat een hogere 
variabiliteit in systolische en diastolische bloeddruk gerelateerd is aan een slechtere cog-
nitieve functie, ongeacht de waarde van de gemiddelde bloeddruk. Verder lieten we zien 
dat hogere bloeddrukvariabiliteit gepaard ging met een lager volume van de hippocampus 
en een hoger risico op corticale infarcten en cerebrale microbloedingen. Aangezien be-
kend is dat een lager hippocampus volume en meer schade in de kleine vaten van de 




onze resultaten zijn.(27, 28) Omdat eerdere studies lieten zien dat bloeddrukverlagende 
medicatie leidt tot veranderingen in bloeddrukvariabiliteit, veronderstelden we dat bloed-
drukverlagende medicatie de relatie tussen bloeddrukvariabiliteit en cognitief functioneren 
zou kunnen mediëren.(29) In hoofdstuk 4 lieten we zien dat het gebruik van bètablokkers 
en renine-angiotensine-systeem remmers gepaard gaat met een hogere variabiliteit in sys-
tolische bloeddruk. Echter, bloeddrukverlagende medicatie had geen invloed op de relatie 
tussen bloeddrukvariabiliteit en cognitief functioneren. Dit ondersteunt onze bevinding 
dat bloeddrukvariabiliteit, onafhankelijk van bloeddrukverlagende medicatie, gerelateerd 
is aan een slechtere cognitieve functie. Omdat deze relatie slechts op één tijdspunt geana-
lyseerd werd, is longitudinaal onderzoek nodig om de causaliteit te kunnen onderzoeken. 
In het tweede deel van dit proefschrift laten we twee studies zien die de relatie tussen 
vroege markers van hartschade in relatie tot cognitief functioneren onderzochten. In 
hoofdstuk 5 toonden we aan dat N-terminal pro-brain natriuretic peptide (NT-proBNP), 
een neurohormoon dat gebruikt wordt bij het diagnosticeren van klinisch hartfalen, gere-
lateerd was aan slechtere cognitieve functie op baseline en een snellere achteruitgang in 
cognitie tijdens een studieperiode van ongeveer drie jaar. Een mogelijke verklaring hiervoor 
is dat hogere waarden van NT-proBNP kunnen duiden op een suboptimale contractie van 
de linkerventrikel, met verminderde cerebrale hypoperfusie tot gevolg.(30) Hoofdstuk 6 
onderzocht de relatie tussen cardiaal troponine T (cTnT), een proteïne dat gebruikt wordt 
bij de diagnose van een acuut myocardinfarct, en cognitief functioneren. We toonden 
aan dat mensen met hogere waarden van cTnT een slechtere cognitie op baseline hadden 
en  tevens een snellere achteruitgang in cognitief functioneren lieten zien. Het feit dat 
we dezelfde resultaten vonden bij mensen met een laag NT-proBNP, maakt het minder 
waarschijnlijk dat een verminderde linkerventrikelfunctie leidend tot verminderde cerebrale 
hypoperfusie hieraan ten grondslag ligt. Dit geeft aanleiding tot verdere speculatie over 
andere mechanismen. Omdat cTnT recent is aangetoond in vasculaire gladde spiercellen, 
kunnen we hypothetiseren dat hoge cTnT waarden wijzen op schade aan vasculaire gladde 
spiercellen in een vroege fase, vóór de manifestatie van (subklinische) ziekten.(31) Hierbij 
kunnen we speculeren dat cTnT niet alleen door cardiomyocyten wordt afgegeven, maar 
ook door gladde spiercellen van bijvoorbeeld de microvasculatuur van de hersenen. Hoge 
cTnT waarden zouden daardoor een aanwijzing kunnen zijn voor structurele hersenschade, 
wat cognitieve stoornissen veroorzaakt. Dit onderzoek laat in ieder geval zien dat vroege 
identificatie en behandeling van hartschade en microvasculaire schade belangrijk zijn om 
uiteindelijke cognitieve veroudering te vertragen of voorkomen. Toekomstig onderzoek 
dat zich richt op de relatie van NT-proBNP en cTnT met hersenperfusie, hersenvolume en 
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structuur van de kleine vaten is raadzaam om meer te weten te komen over het onderlig-
gende mechanisme.
In het laatste deel van dit proefschrift introduceerden we een nieuwe onderzoekstechniek, 
genaamd iVitality (hoofdstuk 7). iVitality bestaat uit een website, een smartphone ap-
plicatie en gezondheidssensoren, die het mogelijk maken om indicatoren van gezondheid 
thuis te kunnen meten. In een proof-of-principle studie includeerden we 151 mensen en 
evalueerden we of smartphone-technologie bruikbaar is bij het langdurig monitoren van 
bloeddruk gemeten in de thuissituatie. We toonden aan dat 1) de correlatie tussen thuis 
gemeten bloeddruk en bloeddruk gemeten in de kliniek hoog was; 2) het aantal deelnemers 
dat de bloeddrukmetingen thuis uitvoerde, hoog was; en 3) de systolische en diastolische 
bloeddruk van deelnemers die naar de huisarts werden verwezen in verband met een hoge 
bloeddruk, significant verbeterde. Deze bevindingen zijn veelbelovend in het kader van een 
alternatieve onderzoeksmethode om op grote schaal gezondheidskarakteristieken thuis te 
kunnen meten. Omdat het opsporen en controleren van een hoge bloeddruk hersencom-
plicaties voorkomt, zou het daarnaast gebruikt kunnen worden als preventieve methode 
om uiteindelijk cognitieve achteruitgang te voorkomen. Deze mogelijkheden dienen verder 
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